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ABSTRACT 
 
Caroline Njeri Maina 
 
 
OBSTACLES AND CIRCUMVENTION STRATEGIES FOR HEMATOPOIETIC STEM CELL 
TRANSDUCTION BY RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS 
 
 High-efficiency transduction of hematopoietic stem cells (HSCs) by recombinant 
adeno-associated virus serotype 2 (AAV2) vectors is limited by (i) inadequate expression 
of cellular receptor/co-receptors for AAV2; (ii) impaired intracellular trafficking and 
uncoating in the nucleus; (iii) failure of the genome to undergo second-strand DNA 
synthesis; and (iv) use of sub-optimal promoters.  Systematic studies were undertaken to 
develop alternative strategies to achieve high-efficiency transduction of primary murine 
HSCs and lineage-restricted transgene expression in a bone marrow transplant model in 
vivo. These included the use of: (i) additional AAV serotype (AAV1, AAV7, AAV8, 
AAV10) vectors; (ii) self-complementary AAV (scAAV) vectors; and (iii) erythroid cell-
specific promoters. scAAV1 and scAAV7 vectors containing an enhanced green-
fluorescent protein (EGFP) reporter gene under the control of hematopoietic cell-specific 
enhancers/promoters allowed sustained transgene expression in an erythroid lineage-
restricted manner in both primary and secondary transplant recipient mice.  
 Self complementary AAV vectors containing an anti-sickling human β-globin 
gene under the control of either the β-globin gene promoter/enhancer, or the human 
parvovirus B19 promoter at map-unit 6 (B19p6) were tested for their efficacy in a human 
erythroid cell line (K562), and in primary murine hematopoietic progenitor cells (c-kit
+
, 
lin
-
). These studies revealed that (i) scAAV2-β-globin vectors containing only the HS2 
enhancer are more efficient than ssAAV2-β-globin vectors containing the 
v 
 
HS2+HS3+HS4 enhancers; (ii) scAAV-β-globin vectors containing only the B19p6 
promoter are more efficient than their counterparts containing the HS2 enhancer/β-globin 
promoter; and (iii) scAAV2-B19p6-β-globin vectors in K562 cells, and scAAV1-B19p6-
β-globin vectors in murine c-kit+, lin- cells, yield efficient expression of the β-globin 
protein. These studies suggest that the combined use of scAAV serotype vectors and the 
B19p6 promoter may lead to expression of therapeutic levels of β-globin gene in human 
erythroid cells, which has implications in the potential gene therapy of β-thalassemia and 
sickle cell disease.  
 
     Arun Srivastava, Ph.D., Chair 
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 1 
INTRODUCTION 
 Adeno-associated virus 2 (AAV2) is a small, non-enveloped, icosahedral virus of 
approximately 22 nm (Berns,1990; Siegl et al., 1985). AAV2 belongs to the Parvoviridae 
family and since co-infection with a helper virus is required for productive infection to 
occur, AAV is assigned to the Dependovirus genus (Siegl et al., 1985). The other two 
genera within the parvoviridae family are Parvovirus; which consists of human 
parvovirus B19 and minute virus of mice, and Densovirus; which consists of Galleria 
densovirus and Junonia densovirus (Siegl et al., 1985). AAV2 was isolated from rhesus 
monkey kidney cells in 1965 as a contaminant of adenovirus preparations. (Atchison et 
al., 1965). 
 
A. AAV2 Genome 
 AAV2 consist of a single-stranded DNA genome of 4680 nucleotides (Srivastava 
et al., 1983). The terminal 145 nucleotides forms the inverted terminal repeat (ITR) 
consisting of the T-shaped hairpin of 125 bases and the D sequence of 20 bases (Koczot 
et al., 1973).  The ITR provides a free 3’ hydroxyl group which serves as the origin of 
replication.  In addition, the ITR has sequences that are needed for integration, rescue and 
encapsidation (Beaton et al., 1989; Labow et al., 1986; Labow et al., 1988; Samulski et 
al., 1983; Samulski et al., 1989; Senapathy et al., 1984; Tratschin et al., 1984). A cellular 
protein, later identified as FK506 binding protein, FKBP52, has been shown to bind to 
the D sequence and regulate viral second strand synthesis (Qing et al., 1997; Qing et al., 
1998; Srivastava et al., 1983; Wang et al., 1995a; Wang et al., 1996). Within the ITR are 
two open reading frames encoding the rep (replication) and cap (capsid) genes. The rep 
gene, which is under the control of two promoters located at map position 5 (p5) and 19 
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(p19), encodes four non-structural proteins named Rep78, Rep68, Rep52 and Rep40, 
which are named based on their molecular weights (Mendelson et al., 1986; Trempe et 
al., 1987). While all the Rep proteins possess ATPase and helicase activities, (Collaco et 
al., 2003; Im et al., 1990; Smith et al., 1998), Rep 78 and 68 also exhibit endonuclease 
and site-specific DNA binding activities, which play a role in AAV2 DNA replication 
(Berns et al., 1996). In addition, Rep 78 and 68 are also involved in regulating AAV gene 
transcription during a productive infection (Pereira et al., 1997).   
 The cap gene is under the control of a single promoter at map position 40 (p40) 
and encodes three structural proteins, VP1, VP2 and VP3 in a ratio of 1:1:10 with 
molecular weights of 87, 73, and 61 kDa, respectively. Processing of the cap mRNA by 
alternative splicing and translation initiation from two different sites allows the synthesis 
of the three cap proteins from a single promoter. VP1 is generated from the larger 
transcript, while VP2 and VP3 are generated from the smaller transcript at the ACG and 
AUG initiation codons, respectively (Becerra et al., 1988; Cassinotti et al., 1988; Siegl et 
al., 1985; Trempe et al., 1988). 
 
B. AAV serotypes 
  Since the tissue tropism of AAV2 is relatively broad, efforts are currently 
underway to understand the biology and infection profiles of other AAV serotypes. 
Having additional serotypes allows for use of less viral load if the alternative serotype has 
a better transduction profile and also helps evade the immune system if the recipient is 
seropositive for AAV2. Up to date, there are approximately 11 AAV serotypes and over 
100 variants that have been isolated from human/non-human primates and adenovirus 
stocks (Atchison et al., 1965; Bantel-Schaal et al., 1984; Gao et al., 2004; Gao et al., 
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2002; Hoggan et al., 1966; Mori et al., 2004; Parks et al., 1967; Rutledge et al., 1998; 
Schmidt et al., 2006). Some of the newly isolated serotypes have a different tropism and 
enhanced transduction over AAV2. AAV1 and AAV7 have a propensity for muscle (Gao 
et al., 2004; Gao et al., 2002), AAV5 for the central nervous system (Alisky et al., 2000; 
Burger et al., 2004), and AAV8 for the liver (Gao et al., 2004; Gao et al., 2002).   
C. AAV receptor and co-receptors 
 The primary attachment receptor for AAV2 was identified as heparan sulfate 
proteoglycan (Summerford et al., 1998), while fibroblast growth factor receptor 1(Qing et 
al., 1999), α5βV integrin (Summerford et al., 1999) and hepatocyte growth factor 
receptor, c-Met (Kashiwakura et al., 2005) were identified as coreceptors. Although 
several other AAV serotypes have also become available, the receptors for some these 
serotypes have not yet been identified. The binding of AAV3 is inhibited by heparin, 
implying that it may also use HSPG as an attachment receptor (Handa et al., 2000; 
Rabinowitz et al., 2002). AAV4 and AAV5 utilize sialic acid as a receptor, with AAV5 
and AAV4 utilizing the N-linked sialic acid and O-linked sialic acid moeties, respectively 
(Kaludov et al., 2001; Walters et al., 2001). In addition, platelet-derived growth factor 
receptor has been identified as the receptor for AAV5 (Di et al., 2003). To date, the 
receptors for AAV1, AAV6, AAV7, AAV8, AAV9 and AAV10 remain to be identified.  
 
D. AAV entry 
 The mechanism AAV entry into cells has been mainly studied in AAV2. Using 
real-time tracking of fluorescence labeled AAV2, entry of AAV2 has been shown to 
occur at a very rapid rate of 100 msec (Seisenberger et al., 2001). Following binding to 
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the primary receptor, AAV enters the cell in dynamin-dependent, clathrin-coated pits 
(Bartlett et al., 2000; Duan et al., 1999a). Although the mechanism is not fully 
understood, interaction of the virus with the cell receptor and co-receptor is believed to 
trigger Rac1/phosphatidylinositol 3-kinase (PI3-kinase)-dependent signal transduction 
pathway that results in endocytosis of the virus (Sanlioglu et al., 2000). 
 
E. Intracellular trafficking and uncoating of AAV2 
 In permissive cells, AAV traffics through early and late endosomes, while in less 
permissive cells, AAV2 fails to enter the late endosome (LE) (Hansen et al., 2001a). 
Following endocytosis, AAV2 migrates through early and late endosomes in a Rab 
GTPase dependent manner before entering the nucleus. Early endosomes are routed 
either to the late endosome or the perinuclear recycling endosome (PNRE). The virus 
then escapes from the LE or PNRE or gets transported to the golgi prior to its escape into 
the nucleus (Ding et al., 2005). Several studies have shown that acidication in the late 
endosome and lysosomal compartments may play a role in activating “competency” of 
the virus for transduction (Douar et al., 2001; Hansen et al., 2001a; Parker et al., 2000; 
Xiao et al., 2002). Movement of free virus in the cytoplasm and nucleus may be 
facilitated by ATP-dependent molecular motors. Nucleolin, a protein that shuttle between 
the cytoplasm and the nucleus has been shown to interact with AAV2 virions (Qiu et al., 
1999).  In addition, Zhao and colleagues documented that FKBP52 interacts with intact 
AAV2 capsid and the retrograde motor protein, dynein, and facilitates intracellular 
trafficking of AAV2 (Zhao et al., 2006). The ubiquitin-proteosome pathway has also 
been shown to play a role in nuclear transport and capsid disassembly (Yan et al., 2002b). 
Inhibition of EGFR-PTK, a kinase that phosphorylates FKBP52 at tyrosine residues, was 
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recently shown to decrease ubiquitination of AAV2 capsids (Zhong et al., 2007). Since 
ubiquitination is required for the proteasome-mediated degradation of AAV2 vectors, less 
ubiquitination improved the nuclear transport of AAV2 vectors. Whether uncoating 
occurs inside or outside the nucleus is still unknown. Hansen and colleagues documented 
infection of purified nuclei from both permissive and non-permissive cells, indicating that 
the nucleus contains all the machinery necessary for uncoating (Hansen et al., 2001b). 
While uncoating of AAV2 in primary murine hepatocytes is inefficient, uncoating of 
AAV8 occurred rapidly in these cells (Thomas et al., 2004). 
 
F. Viral second-strand DNA synthesis 
 Since AAV2 is a single-stranded virus, conversion of it genome to a double-
stranded form is required for it to be transcriptionally active. Several studies have 
indicated that conversion to double stranded genome is a major limiting step in AAV2 
transduction (Ferrari et al., 1996; Fisher et al., 1996). Treatment of cells with adenovirus, 
E4ORF6 gene and genotoxic agents has been shown to improve transduction of cells by 
AAV2 by improving the conversion of single-stranded DNA genomes to duplex forms 
(Alexander et al., 1994; Hillgenberg et al., 1999; Sanlioglu et al., 1999; Yalkinoglu et al., 
1988). In 1997, Qing et. al identified a cellular protein that interacts with the D-sequence 
in the AAV2 ITR, and regulates viral second strand DNA synthesis (Qing et al., 1997). 
The protein was later identified as a cellular protein that binds the immunosuppressant 
drug FK506, known as FK506-binding protein (FKBP52) (Qing et al., 2001). FKBP52 
can be phosphorylated at tyrosine residues by epidermal growth factor receptor tyrosine 
kinase (EGFR-PTK) and at serine/threonine residues by a yet unidentified kinase. 
Phosphorylation at tyrosine residues has been shown to inhibit viral second strand 
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synthesis by approximately 90%, while phosphorylation at serine/threonine residues 
inhibits transduction by about 40% (Qing et al., 1998). Later, the group reported that 
FKBP52 was dephosphorylated at tyrosine residues by the cellular T cell protein tyrosine 
phosphatase (TC-PTP) (Qing et al., 2003; Zhong et al., 2004b), and at serine/threonine 
residues by protein phosphatase 5 (PP5), (Zhao et al., 2007) which leads to an increase in  
the transduction efficiency of AAV2 vectors. 
 
G. AAV2 life cycle  
 AAV2 can follow two pathways in its life cyle that are known as the lytic or 
lysogenic pathways. The lytic pathway develops when AAV2 is co-infected with a helper 
virus such as adenovirus, vaccinia and herpes virus (Buller et al., 1981; Schlehofer et al., 
1986).  In the presence of helper virus, the provirus genome is rescued from host 
chromosome in a Rep-dependent manner, and then replicated and packaged into virions.   
Following lysis of host cell, the newly assembled virions are released (Mendelson et al., 
1988; Tratschin et al., 1985; Wang et al., 1995a; Wang et al., 1996).  Treatment with 
genotoxic agents can also lead to a productive infection although the viral yield is much 
lower than that in the presence of a helper virus (Schlehofer et al., 1986; Yakobson et al., 
1987; Yalkinoglu et al., 1988).  In the absence of helper virus, AAV2 undergoes latency 
by integrating site-specifically into a region of chromosome 19 (19q13.3) designated 
AAVS1 (Cheung et al., 1980; Handa et al., 1977; Kotin et al., 1990; Kotin et al., 1991; 
Kotin et al., 1992; Samulski et al., 1991). The viral components required for site-specific 
integration are the AAV ITRs, in cis and Rep 78/68, in trans (Surosky et al., 1997; 
Weitzman et al., 1994; Young, Jr. et al., 2000; Young, Jr. et al., 2001).  Another cis –
element that harbors the Rep-binding element (RBE) and also overlaps with the p5 
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promoter has also been shown to be necessary site-specific integration (Philpott et al., 
2002b; Philpott et al., 2002a).  The AAVS1 locus has recently been shown to be in close 
proximity with the muscle-specific genes p85 (Tan et al., 2001a), TNNT1 and TNN13 
(Dutheil et al., 2000). An insulator within this locus has also been identified (Ogata et al., 
2003).   
 
H. Recombinant AAV vectors and gene therapy 
 Gene therapy offers great promise for the treatment of genetic and acquired 
human diseases and viral-based vectors have emerged as the most efficient gene delivery 
systems. Viruses can easily be manipulated to express therapeutic genes since they have 
evolved to effectively infect and replicate in specific cell types. The commonly used 
viruses in gene therapy are retrovirus, adenovirus, adeno-associated virus and herpes 
simplex virus. Although retroviruses were the first vectors used in a human clinical trial 
for adenosine deaminase deficiency (SCID-ADA) success with these vectors has been 
hampered by several obstacles (Blaese et al., 1992; Culver et al., 1991b; Culver et al., 
1991a). First, retrovirus vectors were initially based on the Moloney murine leukemia 
virus (MoMLV). These vectors are incapable of crossing the nuclear membrane and 
consequently, infect only dividing cells (Havenga et al., 1997). In hematopoietic gene 
transfer, cells have to be induced to divide which also induces differentiation and loss of 
the stem cells properties (Glimm et al., 1997). Further, although retroviruses integrate 
into the host genome, prolonged expression has been difficult to achieve. Retroviruses are 
inactivated by c1-complement and anti-α galactosyl antibodies, both present in human 
sera (Rollins et al., 1996; Rother et al., 1995). In addition, retroviruses have also been 
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associated with oncogenesis through insertional mutagenesis upstream of the LMO2 
protooncogene in three patients from the X-linked immunodeficiency SCID-X1 clinical 
trial (Hacein-Bey-Abina et al., 2003a; Hacein-Bey-Abina et al., 2003b).   Lentiviruses, 
based on the human immunodeficiency virus (HIV) or equine infectious anemia (EIAV), 
have emerged as alternatives to the conventional retroviruses due to their ability to infect 
non-dividing cells (Uchida et al., 1998; Whittaker et al., 1998). However, a high 
frequency of liver cancer was reported in mice infected with EIAV-based lentiviruses and 
the highly pathogenic nature of HIV is still a serious safety concern (Deglon et al., 2000; 
Schnell et al., 2000; Themis et al., 2005; Wu et al., 2000). Adenoviruses possess several 
qualities that make them an attractive vector for gene therapy of certain human diseases. 
First, adenoviruses use the ubiquitously expressed Coxsackie and adenovirus receptor 
(CAR) as primary receptor and αv integrins for entry, allowing them to have a broad host 
range (Bergelson et al., 1997; Tomko et al., 1997; Wickham et al., 1993). In addition, 
adenovirus vectors which can be produced to very high titers, can infect both dividing 
and non-dividing cells (Hutchins et al., 2000). However, since adenoviruses do not 
integrate into the host genome, expression is only transient (Engelhardt et al., 1993a; 
Engelhardt et al., 1993b; Hitt et al., 1997; Young et al., 2006). Further, the highly 
immunogenic nature of adenovirus, which resulted in the death of a patient undergoing 
treatment to correct ornithine transcabamylase deficiency, remains a very serious concern 
(Young et al., 2006). Because herpes simplex virus is a highly neurotropic virus, gene 
therapy efforts have been mainly focused in the nervous system. Several trials using 
mutant HSV1 to treat glioma have highlighted the efficacy of this virus to treat tumors 
that overexpress cellular enzymes such as thymidine kinase and ribonucleotide reductase 
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(Harrow et al., 2004; Papanastassiou et al., 2002; Rampling et al., 2000). There is still 
concern that neuropathic effects may develop due to the high tropism of HSV for 
neuronal cells (Wolfe et al., 2004).  
 Adeno-associated virus 2, a single-stranded, non-pathogenic human parvovirus, 
has gained attention as a potentially safe vector for gene therapy and transfer (Conlon et 
al., 2004; Marshall., 2001). AAV2 infects a wide variety of cells (Flotte et al., 1993; 
Griffey et al., 2005; Kaplitt et al., 1994; Kessler et al., 1996; McCown et al., 1996; 
Muzyczka,1992; Snyder et al., 1997; Xiao et al., 1996; Yang et al., 2002),  allowing them 
to be used in gene therapy trials of several human diseases.  AAV2-based vectors are 
currently in phase I/II clinical trials for gene therapy of a number of diseases such as, 
cystic fibrosis, hemophilia B and α-1 anti-trypsin deficiency (Aitken et al., 2001; Flotte 
et al., 1996; Flotte et al., 2004; Kay et al., 2000; Manno et al., 2003; Snyder et al., 2005; 
Wagner et al., 2002). While wt-AAV integrates site specifically on chromosome 19, 
recombinant AAV integrates randomly into the host genome at the site of double 
stranded (ds) DNA breaks (McCarty et al., 2004; Miller et al., 2004).  On the other hand, 
in post-mitotic tissues like muscle, brain and retina, majority of AAV vectors fail to 
integrate and have been shown to persist as head-to-tail concatemers (Chao et al., 1999; 
Duan et al., 1998; Duan et al., 1999b; Yan et al., 2005). However, the small transgene 
capacity of approximately 5 kb remains a serious hurdle (Samulski et al., 1989). The 
advent of split dual vectors, where a gene is split into two vectors that are simultaneously 
delivered has increased the transgene capacity, although the efficiency of concatemer 
formation and transgene expression is still low (Duan et al., 2000; Duan et al., 2001; Lai 
et al., 2006; Nakai et al., 2000; Reich et al., 2003; Sun et al., 2000; Yan et al., 2000).  
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I. Self-complementary AAV vectors 
 Transduction of cells by recombinant AAV vectors is limited by the requirement 
to convert its single stranded genome to a transcriptionally active double-stranded form 
(Ferrari et al., 1996; Fisher et al., 1996). During packaging of wild-type AAV, atypical 
genomes consisting of inverted repeats are formed (de la Maza et al., 1980). These 
particles are called defective interfering particles (DI). Ensuing studies showed that 
rAAV DNA of half the size of wt AAV could also be packaged as dimers that are similar 
to a DI particle (Dong et al., 1996; Hirata et al., 2000; Muzyczka,1992). These vectors 
are now referred to as self-complementary AAV vectors because they by-pass the need 
for second-strand synthesis (McCarty et al., 2001; Wang et al., 2003).  Because the 
scAAV vector was a by-product of ssAAV vector production, high titer stocks were 
difficult to achieve. To generate AAV vectors that predominantly packaged dsDNA 
genome, Wang et al introduced a mutation in one of the AAV ITRs. By deleting the D-
sequence and the terminal resolution site (trs) on the left ITR, the dimers fail to resolve 
into monomers ensuring that only a double stranded genome is packaged by the other 
intact ITR (Wang et al., 2003). McCarty et al also made a similar scAAV vector by only 
deleting the trs from one of the ITRs (McCarty et al., 2003).  Several studies have 
confirmed the previous observation that these vectors can mediate rapid and high 
efficiency transduction in several cell types in vitro and in vivo (Aldrich et al., 2006; Fu 
et al., 2003; Gao et al., 2006; Nathwani et al., 2007; Ren et al., 2005; Sipo et al., 2007; 
Veron et al., 2007; Wu et al., 2007; Yokoi et al., 2007).  
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J. Transduction of hematopoietic cells by recombinant AAV vectors 
 Three sets of opinions exist regarding transduction of human hematopoietic cells 
by recombinant AAV2 vectors. First, primary human hematopoietic cells are impervious 
to transduction by AAV and that the observed transgene expression was due to “pseudo-
transduction” by contaminants in the AAV viral stock (Alexander et al., 1997). The 
second opinion is that primary human hematopoietic cells can be transduced by AAV 
vectors but only at a high vector:cell ratio (approximately 10
6
 particles/cell) (Hargrove et 
al., 1997; Malik et al., 1997; Nathwani et al., 2000). Still we and others have achieved 
successful transduction at a low vector:cell ratio (Chatterjee et al., 1999; Lubovy et al., 
1996; Ponnazhagan et al., 1997a; Ponnazhagan et al., 1997b; Santat et al., 2005; Zhou et 
al., 1994). To resolve this controversy, Ponnazhagan et al (Ponnazhagan et al., 1997a) 
undertook a systematic study in which they used CD34
+
 cells from 12 healthy donors, 
and infected them under identical conditions with 10
5
 particles per cell of recombinant 
AAV2-lacZ vector. Only CD34
+
 cells from 6 of the 12 donors studied had significant 
lacZ expression (15-80%), and the rest had no detectable lacZ gene expression. In 
addition, they documented binding of 
35
S-labeled AAV to CD34
+
 cells from a positive 
donor and not a negative donor which reinforced the group’s hypothesis that AAV 
infection required a cellular receptor. A year later, cell surface heparan sulfate 
proteoglycan (HSPG) was identified as an attachment receptor for AAV2 (Summerford et 
al., 1998). Subsequent studies identified fibroblast growth factor receptor 1 (FGFR1) 
(Qing et al., 1999), αvβ5 integrin (Summerford et al., 1999) and hepatocyte growth 
factor receptor (c-met) as coreceptors for AAV2 (Kashiwakura et al., 2005). 
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  In addition to the lack of receptor and/or coreceptor  in some donor CD34
+
 cells, 
conversion of AAV2 single stranded genome to a transcriptionally active double stranded 
genome is still a rate-limiting step (Ferrari et al., 1996; Fisher et al., 1996).  A more 
comprehensive study of recombinant AAV2 mediated transduction of primary murine 
hematopoietic stem cells (HSCs) has revealed more obstacles to AAV2 mediated 
transduction of these cells.  Similar, to the primary human hematopoietic cells, the lack of 
co-expression of the receptor (HSPG) and co-receptor (FGFR1, αvβ5 integrin)  of AAV2 
remains a rate limiting step in the transduction of primary murine HSCs. While 
approximately 50% of primary murine HSCs express HSPG and 40-60% express FGFR1, 
only 10% of these cells co-express both receptors (Zhong et al., 2004b). Based on the 
previous observation that the phosphorylated forms of FKBP52 inhibits second strand 
synthesis, Qing and colleagues made FKBP52 knock-out mice (FKBP52-KO) based on 
the premise that complete removal of the inhibitory tyrosine and serine/threonine 
phosphorylated forms, would improve AAV mediated transduction of primary murine 
HSCs. The group also made TC-PTP transgenic mice (TC-PTP-TG) which would only 
have the dephosphorylated forms of FKBP52, and most likely have efficient transduction 
by AAV2 vectors.  Following transduction of normal control, FKBP52-KO and TC-PTP-
TG mice, little transduction was observed in normal control mice, while transduction was 
improved by 3- and 10-fold in the FKBP52-KO and TC-PTP-TG mice, respectively. 
There results confirmed that conversion of ssAAV2 to a double stranded form was a rate 
limiting step in the transduction of these cells. The group has also recently shown that co-
infection of AAV1 with self-complementary AAV2 vectors containing the TC-PTP gene 
improves transduction of murine HSCs in long term transduction studies, confirming that 
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conversion of single stranded AAV2 genome to transcriptionally active double stranded 
genome is a rate limiting step in AAV2 mediated transduction of murine HSCs (Zhong et 
al., 2006a). To determine whether intracellular trafficking was a rate limiting step in the 
transduction of murine HSCS by AAV2 vectors, murine HSCs were transplanted into 
lethally-irradiated syngeneic recipient mice and the nuclear and cytoplasmic fractions 
isolated from spleen colonies 12 days post-transplantation (Zhong et al., 2006a). The 
group observed that the majority of the viral genome was present in the cytoplasmic 
fractions of the control, FKBP52-KO and TC-PTP-TG mice, but treatment with 
hydroxyurea (HU) augmented nuclear transport of the viral genomes. HU treatment 
increased the nuclear fraction from 20% to 60% in the control mice, from 45% to 85% in 
the TC-PTP-TG mice and from 13% to 55% in the FKBP52-KO mice. The reason behind 
the low viral genomes in the nuclear fraction of FKBP52-KO mice was not evident at the 
time. However, in recent studies, FKBP52 has been shown to be a cellular chaperone and 
may have an additional role of trafficking AAV into the nucleus (Zhao et al., 2006). 
Despite the improved trafficking in mice overexpressing TC-PTP in the TC-PTP-TG or 
in all groups following HU treatment, the group found that majority of the viral genome 
remained single stranded. In addition, a significant number of viral genomes in the 
cytoplasmic and the nuclear fraction was resistant to DNase I treatment, indicating that 
the virus had failed to undergo uncoating. Thus, although HU treatment improved 
trafficking and second strand synthesis in these cells, the effect was minimal since the 
majority of the virus remained uncoated in the murine HSCs for at least 48 hrs post-
transduction.  
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K. Strategies to improve transduction of HSCs 
  (i) Self-complementary AAV vectors 
 While transduction from single stranded AAV vectors is low in murine HSCs 
(Qing et al., 2003; Zhong et al., 2004b), transduction from double stranded self-
complementary AAV vectors is readily detectable (Zhong et al., 2006a, Maina., 2008a) 
In a comparative study of scAAV1-, scAAV2-, scAAV3- and scAAV5-mediated 
transduction of murine HSCs in 7-day liquid cultures, scAAV1 mediated transgene 
expression in 5% of these cells. Expression from scAAV2 was 2%, while expression 
from scAAV3 and scAAV5 was insignificant. These results confirm that second strand 
synthesis is a rate limiting step in the transduction of these cells. Although scAAV 
vectors have been shown to overcome the limitation of second strand synthesis, their use 
is restricted to small transgene cassettes. However, Wu et al, have recently shown that the 
packaging capacity of scAAV vectors can be increased from 2.5 kb to 3.3 kb (Wu et al., 
2007). For transgene cassettes larger than 3.3 kb, conversion of single stranded AAV 
vectors can be facilitated through the use of scAAV-TC-PTP and scAAV-PP5 as helper 
viruses (Zhao et al., 2007; Zhong et al., 2006a).  In a long-term bone marrow transduction 
study, Zhong and colleagues showed that co-infection of single stranded AAV1 vectors 
with scAAV2 vectors containing the TC-PTP gene improved transduction of murine 
HSCs, by presumably increasing conversion of single stranded AAV genome to double 
stranded forms (Zhong et al., 2006a). In a recent study, Zhao and colleagues have also 
shown that dephosphorylation of FKBP52 at serine/threonine residues by PP5 can also be 
exploited to increase the transduction efficiency of ssAAV vectors (Zhao et al., 2007).  
Another strategy to increase the packaging capacity of self-complementary vectors is to 
employ the split dual vector strategy in which a gene is split into two scAAV vectors 
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(Chao et al., 2002; Duan et al., 2000; Duan et al., 2001; Ghosh et al., 2006; Ghosh et al., 
2007b; Lai et al., 2006; Nakai et al., 2000; Reich et al., 2003; Sun et al., 2000; Xu et al., 
2004; Yan et al., 2000; Yan et al., 2002a; Yan et al., 2005, Maina, 2008b). In this 
strategy, a single gene is split into two separate scAAV vectors, which then undergo 
intermolecular recombination following cellular entry and viral uncoating. Using a split 
GFP vector, Choi and colleagues provided evidence that the closed-to-closed ITRs were 
more efficient than the open-to-open ITRs at undergoing recombination (Choi et al., 
2005). The efficiency of recombination can also be improved through the inclusion of a 
600bp fragment of the alkaline phosphatase gene (AP) in the two split vectors (Ghosh et 
al., 2008). 
 
  (ii) Use of serotypes other than AAV2 
 In short and long term transduction studies using AAV serotypes 1, 2, 3 and 5, 
Zhong and colleagues documented improved transduction with AAV serotype 1 in 
murine HSCs (Zhong et al., 2006a). Approximately 9% of progenitor cell assay colonies 
established from Sca1
+
, c-kit
+
, lin
-
 cells, infected with AAV1, expressed the transgene. In 
bone marrow transplantation studies, 2% and 7% of peripheral blood (PB) cells from 
mice infected with AAV1 or co-infected with AAV1 and scAAV-TC-PTP vectors, 
expressed the transgene 6 months post transplant, respectively. In addition, 21% of bone 
marrow derived colonies contained the proviral genome in integrated forms. These 
studies document that AAV1 is by far the most efficient serotype in transducing murine 
HSCs. In a separate study involving transduction of human and murine HSCs in vitro and 
in vivo , Li and colleagues demonstrated that AAV7 and AAV8 were the most efficient in 
transducing murine HSCs, while AAV7 followed by AAV8 and AAV1, were the most 
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efficient in transducing human CD34
+
 cells (Li et al., 2005). Thus, AAV7, AAV8 and 
AAV1 are by far the most efficient serotypes for gene transfer of HSCs. Further studies 
with hematopoietic stem cell promoters and scAAV genomes should further augment the 
transduction efficiency of HSCs by AAV1/7/8 serotypes. 
 
  (iii) Use of hematopoietic stem/progenitor cell-specific promoters 
 In all recent studies with murine hematopoietic stem/progenitor cells, 
investigators have used AAV vectors containing a transgene under the control of the 
CMV promoter.  Several studies have shown the inability of CMV promoter to sustain 
long-term expression in various tissue types in vivo.  In 1998, Nakai et al. reported high 
and sustained expression (6 months) of FIX using EF1-α promoter, whereas expression 
from the CMV promoter was lower and transient (5 weeks) despite the persistence of the 
vector genome in the mouse liver (Nakai et al., 1998) Similar results were reported by 
Cordier et al., using AAV vectors to deliver γ-sarcoglycan intramuscularly in a mouse 
model of muscular dystrophy.  While the muscle creatine kinase promoter allowed 
expression of therapeutic levels of γ-sarcoglycan for 11 months, the CMV-driven vector 
expression was sub-therapeutic and declined significantly in 3 months (Cordier et al., 
2001).  In the hematopoietic lineage, Kurpad et al. reported transient, ubiquitous, CMV 
promoter-driven expression of a reporter gene using AAV vectors in primary human 
hematopoietic cells in vitro, while expression from the human β-globin promoter and the 
parvovirus B19 promoter at map unit 6 (B19p6) was sustained and restricted to the 
erythroid lineage (Kurpad et al., 1999).  Similar results were reported by Gardner et al. in 
T cells where they reported robust but transient expression from the CMV promoter 
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(Gardner et al., 1997). Several reports have indicated that the relatively weak expression 
from the CMV promoter is very sensitive to silencing mechanisms in hematopoietic cells 
(Choi et al., 2001; Kung et al., 2000; O'Rourke et al., 2005). Fortunately, other studies 
have explored the potential of eukaryotic and viral promoters to allow high level, tissue 
specific expression in the hematopoietic lineage (Papadakis et al., 2004).  A eukaryotic 
promoter that has been studied extensively is the β-globin promoter with its enhancer 
elements.  The β-globin enhancer consists of five DNase I hypersensitive sites (HS1, 
HS2, HS3, HS4 and HS5), collectively known as the locus control region (LCR), which 
is required for optimal activity of the β-globin promoter (Grosveld et al., 1987; Leboulch 
et al., 1994). Using AAV vectors containing the human β-globin gene under the control 
of the β-globin promoter with a mini-LCR cassette consisting of HS2, HS3 and HS4, Tan 
et al. reported long-term, erythroid specific expression of a human β-globin gene in 
primary murine HSCs from β-thalassemic mice (Tan et al., 2001b). May et al. reported 
phenotypic correction of murine β-thalassemia using a lentiviral vector expressing β-
globin gene under the control of β-globin promoter linked to the core elements of the 
LCR. Tetramers of two human β-globin and two murine α-globin molecules accounted 
for 13% and 17%-24% of the total hemoglobin in mature red cells of normal mice and β-
thalassemic heterozygous mice, respectively (May et al., 2000).  In 2003, Persons and 
colleagues reported similar results albeit at a higher vector number, using a lentiviral 
vector containing the γ-globin gene under the control of the β-globin promoter and 
enhancer elements (Persons et al., 2003). A second promoter that has been extensively 
studied is the promoter for the cell membrane protein, ankyrin, which has been shown to 
direct erythroid-specific expression of γ-globin in transgenic mice (Sabatino et al., 
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2000b). The same group demonstrated long-term expression of γ-globin mRNA in mouse 
erythrocytes from retrovirus vectors containing the human γ-globin gene under the 
control of the ankyrin promoter.  They were able to achieve ~8% of the level of the 
mouse α-globin mRNA, a level that was 50% of the level required to treat severe β-
thalassemia (Sabatino et al., 2000a) Richard et al. demonstrated long-term in vivo 
erythroid-specific expression of ferrochelatase and correction of protoporphyria in a 
mouse model using a self-inactivating lentiviral vector containing ferrochelatase cDNA 
driven by the human ankyrin-1/α-globin HS-40 chimeric promoter/enhancer.   They were 
able to achieve transduction levels that were greater or equal to those achieved by a CMV 
construct and expression was restricted to the erythroid lineage (Richard et al., 2001). 
 Another erythrocyte membrane protein promoter that has been evaluated for 
erythroid-specific expression is the β-spectrin promoter, which is responsible for 
erythrocyte shape and membrane stability and is defective in many patients with 
abnormalities of red blood cell shape including hereditary spherocytosis and 
elliptocytosis (Winkelmann et al., 1993). A viral promoter of significant interest to us is 
the parvovirus B19p6 promoter. Although parvovirus B19 is an autonomously replicating 
virus, its replication is mainly limited to human hematopoietic progenitor cells 
undergoing erythroid differentiation (Ozawa et al., 1986; Ozawa et al., 1987; Srivastava 
et al., 1988).   In human progenitor assays in vitro, activity of B19p6 has been shown to 
be restricted to erythroid lineage (Kurpad et al., 1999; Wang et al., 1995b), but it remains 
to be determined whether expression from this promoter will occur in murine 
hematopoietic cells, presumably because of the absence of a putative transcription factor 
that is required for expression from the B19p6 in human erythroid progenitor cells 
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(Ponnazhagan et al., 1995). Li et al. (Li et al., 2005) have also demonstrated that CMV 
enhancer/chicken β-actin promoter (CBAp) is active in primitive human hematopoietic 
cells.  The stem cell leukemia (SCL) gene is critical for the development of HSCs in the 
embryo (Curtis et al., 2004) and the ability of the SCL promoter to drive gene expression 
in HSCs remains to be explored.  Thus, long-term transgene expression in human and 
murine HSC can be expected to be achieved by using the hematopoietic stem/progenitor 
cell-specific promoters in the context of AAV vectors.  
 
  (iv) Use of Engineered hybrid vectors 
  (a) Mosaic AAV vectors 
 To form an AAV capsid, all AAV serotypes utilize 60 monomers of VP1, VP2 
and VP3. In mosaic AAV vectors, monomers from different serotypes are combined and 
the input ratio of different helper constructs determines the ratio of capsid subunits in the 
mosaic virion (Wu et al., 2006). The benefit of this technique is the ability to combine 
unique features from different serotypes to synergistically enhance transgene expression. 
Rabinowitz and colleagues generated mosaic AAV vectors by pairwise combination of 
AAV serotypes 1 to 5 at different ratios (Rabinowitz et al., 2004). These vectors had dual 
binding characteristics of parent serotypes or new properties different from parental 
viruses.  While neither AAV1 nor AAV2 infect C2C12 muscle cells efficiently, mosaic 
AAV1/2 virions demonstrated enhanced transduction of these cells. As demonstrated 
above, this procedure can be utilized to generate cell type specific vectors with enhanced 
transduction than either of the parent vectors.  
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  (b) Chimeric AAV vectors 
 Chimeric AAV virions are vectors containing capsids that are modified by amino 
acid or domain swapping. This method relies on marker rescue which requires 
cotransfection of an AAV clone carrying a mutation in the capsid gene with wild type 
DNA sequences from a different serotype (Bowles et al., 2003; Hauck et al., 2003; Wu et 
al., 2006). Homologous recombination usually occurs due to the significant degree of 
homology between the AAV serotypes.  The chimeric virions can either be amplified by 
PCR and cloned into a shuttle vector, or transfected onto specific cell types for analysis 
of biological properties. Bowles and colleagues were able to rescue three non-infectious 
clones of AAV2, that could not bind heparin sulfate, by contransfecting the helper 
plasmids with DNA sequences from AAV3 (Bowles et al., 2003). The group 
demonstrated correlation between infectivity and the restoration of heparin binding. 
 
  (c) DNA Shuffling 
 DNA shuffling is an in vitro evolution technique that can be used to generate 
proteins with new phenotypes. In this technique, different alleles are digested and the 
fragments allowed to randomly hybridize, before being amplified in a self-priming PCR 
reaction (Bacher et al., 2002). Soong and colleagues applied this technique to generate 
Moloney Leukemia viruses (MLV) with a different tropism than the parental vectors 
(Soong et al., 2000).  A number of groups have used various combinations of AAV 
serotype vector 1 through 9 to generate vectors with improved transduction ability for 
skeletal muscle, liver, brain  and lung (Grimm et al., 2006; Grimm et al., 2008; Li et al., 
2008).  
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  (d) AAV-Parvovirus B19 hybrid vectors  
 As mentioned above, AAV2 vectors infect a wide variety of cells while 
parvovirus B19 vectors have a narrow tropism for human erythroid progenitors (Ozawa et 
al., 1986; Ozawa et al., 1987; Srivastava et al., 1988; Yaegashi et al., 1989).  Our group 
has combined the advantageous features of these two viruses to generate hybrid AAV-
B19 vectors with remarkable tropism for erythroid progenitors (Ponnazhagan et al., 1998; 
Wang et al., 1995b; Weigel-Kelley et al., 2001; Weigel-Kelley et al., 2002; Weigel-
Kelley et al., 2003). AAV2-B19 virus contains the parvovirus B19p6 promoter 
encapsidated in AAV2 capsid while B19-AAV2 contains the parvovirus B19p6 
promoter-driven vector encapsidated in B19 capsid. As a result, AAV2-B19 vectors 
infect a wide variety of cells but expression is limited to the erythroid cells. On the other 
hand, infection and expression of B19-AAV2 vectors is limited to erythroid cells. 
Recently, we have generated hybrid B19-AAV serotypes 1, 7, 8, and 10 vectors 
containing the B19p6 promoter encapsidated in the respective serotype, with efficient 
transduction of both murine and human HSCs as shown in the Results (Maina et al., 
2008a).  
 
L. Gene Therapy for Sickle Cell Disease 
 Sickle cell disease (SCD) is an autosomal recessive disorder affecting millions of 
people worldwide. The causative mutation is an A-T transversion in the sixth codon of 
the β-globin gene which leads to the substitution of a valine for a glutamic acid, resulting 
in the formation of abnormal hemoglobin, known as hemoglobin S (HbS) (Ingram, 1957). 
Following deoxygenation in red blood cells (RBCs), HbS forms polymers causing the 
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RBCs  to become deformed (sickled) and adherent, leading to vaso-occlusive events, 
resulting in splenic infarct, kidney failure, stroke, painful crises, and chronic anemia 
(Pauling et al., 1949; Bunn et al., 1994; Steinberg et al., 2001). Treatment modalities for 
SCD involves allogeneic bone marrow transplantation, induction of fetal hemoglobin 
(Swank et al., 1998), control of infections, and pain management (Buchanan et al., 2004; 
de Franceschi et al., 2004). Allogeneic transplantation usually requires myeloablative 
conditioning with cyclophosphamide, busulfan, antithymocyte globulin or total lymphoid 
radiation. In addition, cyclosporine and methotrexate are used post-transplant to induce 
immunosuppression (Walters,2005). Hydroxyurea (HU) is the only drug approved by the 
US Food and Drug Administration (FDA) to treat SCD. HU increases HbF in sickle cell 
anemia by inducing erythroid regeneration and augmenting γ-globin gene expression in a 
nitric oxide-dependent pathway (Buchanan et al., 2004; Steinberg, 1999). Other drugs 
that increase HbF and that are currently in Phase I/II clinical trials for SCD are described 
below. Decitibine, an analog of 5-azacytidine induces HbF by causing hypomethylation 
of the γ-globin genes (Saunthararajah et al., 2003). Histone deacetylase (HDAC) 
inhibitors have also been shown to enhance γ-globin gene expression through histone 
hyperacetylation and alteration of chromatin structures (Atweh et al., 1999; Cao et al., 
2004). Autologous bone marrow transplantation with genetically modified cells would be 
a great treatment modality, but has been limited by the inability to achieve therapeutic 
levels of β-globin expression in the HSC’s progeny (Sadelain, 1997; Sadelain, 2006). 
Previously, gene transfer of β-globin gene and its regulatory elements relied on 
oncoretroviruses. However, oncoretroviruses have the disadvantage of requiring cell 
division for nuclear entry, which necessitates the use of cytokines. In addition, these 
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vectors have the problems of low titers, variable expression, vector instability and 
insertional mutagenesis. To overcome these limitations, ‘self-inactivating’ lentiviruses 
have emerged as an alternative to oncoretroviruses. A deletion of the promoters in the U3 
region of both the 3’ and 5’ LTR, results in transcriptional inactivation of the LTR in 
integrated provirus. And as already mentioned above, lentiviruses can infect non-dividing 
cells. May and colleagues were the first to show stable transduction of a lentiviral vector 
carrying the globin gene and a large LCR fragement (3.2kb) and therapeutic correction of 
β-thalassemia intermedia. These studies were followed by others which showed 
therapeutic correction of several β-thalassemia phenotypes, using SIN lentiviral vectors 
expressing β/γ globin, in various mouse models (Hanawa et al., 2004; Imren et al., 2002; 
May et al., 2000; Persons et al., 2003; Puthenveetil et al., 2004; Rivella et al., 2003). 
Therapeutic levels of β/γ globin expression has also been achieved by retroviral and 
lentiviral vectors expressing β-globin (Imren et al., 2004; Oh et al., 2004; Pawliuk et al., 
1998) and phenotypic correction of SCD has been reported in mouse models (Levasseur 
et al., 2003; Pawliuk et al., 2001).   
 Since lentiviral vectors are relatively new, the risks of insertional mutagenesis has 
not been studied in humans. Preliminary results from a a phase I clinical trial with a 
lentiviral vector for HIV gene therapy has so far shown no adverse effects. However, 
several studies have reported the propensity of lentiviral vectors to integrate into genes 
(Imren et al., 2004; Schroder et al., 2002; Wu et al., 2003). Genomic sequencing of vector 
containing fragments from CD34
+
 cells transduced with a lentiviral vector expressing 
anti-sickling β-globin showed that 86% of proviral integration occurred in genes (Imren 
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et al., 2004). Thus the potential for insertional mutagenesis and safety issues with 
lentiviral vectors remains to be addressed.  
 Adeno-associated viral vectors are currently in Phase I/II clinical trials for several 
human diseases and AAV virus has not been implicated in any human disease. As a 
result, AAV vectors offer a safer alternative to the commonly used lentiviral vectors for 
gene therapy of hemoglobinopathies. While several groups had demonstrated erythroid 
restricted expression of globin from an AAV vector in vitro (Walsh et al., 1992) 
(Ponnazhagan et al., 1994) (Einerhand et al., 1995; Miller et al., 1994) (Zhou et al., 
1996),  Ponnazaghan and colleagues were the first to demonstrate AAV mediated 
expression of globin in vivo (Ponnazhagan et al., 1997b). Using a γ-globin gene, under 
the control of the β-globin gene and the HS2 enhancer, they documented a transduction 
efficiency of 8% and transgene expression of approximately 4% at an MOI of 1 and 6% 
at an MOI of 10. However, the level of expression was not very high because these 
experiments were carried out using low density bone marrow cells (LDBM) and not 
enriched hematopoietic stem/progenitor cells. Using an AAV vector containing the 
human β-globin gene under the control of the β-globin promoter with a mini-LCR 
cassette consisting of HS2, HS3 and HS4,  and enriched murine HSCs, Tan et al. reported 
long-term, erythroid specific expression of a human β-globin gene in hematopoietic cells 
from β-thalassemic mice (Tan et al., 2001b). The group showed that the transduced 
globin gene sequences were present at one copy number per cell. While the proviral 
sequences were present in all lineages as determined by PCR analysis, expression was 
limited to the erythroid cells as determined by RT-PCR. In addition, expression level was 
up to 35% of the endogenous murine globin. 
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M. Specific Aims 
The specific aims of the work proposed herein are:  
1) Determine whether transduction of murine hematopoietic/progenitor 
cells can be improved by: (a) Use of additional AAV serotypes 1, 7, 8 and 10; (b) 
Self-complementary, double-stranded AAV-EGFP vectors; and (c) Erythroid 
cell-restricted promoters such the eukaryotic β-globin- and parvovirus B19p6- 
promoters 
To test this hypothesis, hematopoietic stem/progenitor cells were infected with self-
complementary AAV serotype vectors ex vivo, and either cultured in liquid cultures in 
vitro or transplanted into lethally-irradiated congeneic recipients in vivo. EGFP transgene 
expression was determined by flow cytometry 7-days post-transduction for in vitro, or 6-
months post-transduction for in vivo. 
2) Determine whether (a) AAV integrates in bone marrow cells and (b) 
whether AAV-mediated transduction results in any overt toxicity 
(a) DNA from mice transplanted with mock-infected or vector-infected hematopoietic 
stem/progenitor cells were isolated and digested by restriction enzymes that either do not 
cleave, or cleave 1 or 2 times within the expression cassette. Southern blot analysis using 
an EGFP-specific DNA probe was performed to confirm the presence of vector DNA. (b) 
Peripheral blood and bone marrow cells were analyzed morphologically. 
3) Determine whether AAV vectors can mediate expression of β-globin 
in K562 cells and mouse hematopoietic progenitor cells in vitro and in sickle cell 
disease mice in vivo 
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RNA isolated from mock-infected or vector-infected K562 cells was subjected to RT-
PCR analysis with primers specific to vector transcripts. Southern blot analysis with a β-
globin-specific probe was performed to quantify the level of expression. AAV-mediated 
β-globin protein expression in K562 cells and primary murine hematopoietic cells was 
quantified by flow cytometry. Blood and bone marrow cells drawn from mice 
transplanted with hematopoietic stem/progenitor cells that were mock-transduced or 
vector-transduced were analyzed by high performance liquid chromatography (HPLC) 
and isoelectric focusing (IEF) for globin gene expression. The results were compared to 
the endogenous β-globin gene expression.  
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MATERIALS AND METHODS  
A. Cells and plasmids 
 The human erythroleukemia cell line K562 was purchased from the American 
Type Culture Collection (ATCC; Manassas, VA). Cultures were maintained in Iscove’s 
modified Dulbecco’s medium (IMDM) supplemented with 10% newborn calf serum 
(NCS) and 1% penicillin/ streptomycin (Sigma, St. Louis, MO).  
 
B. AAV plasmids and scAAV serotype vectors 
 Plasmids pB19p6 (Zhou et al., 1994) and scAAV-CBAp-EGFP (Wang et al., 
2003) have been previously described. Plasmid pB19p6EGFP was constructed by 
inserting the EGFP gene and the SV40pA from plasmid pEFGP-C1 (AfeI-SphI) into 
plasmid pB19p6 (HincII-SphI). The overall strategy to construct the recombinant AAV 
genomes containing the enhanced green fluorescent protein (EGFP) under the control of  
the parvovirus B19p6 promoter (pB19p6)  and the β-globin promoter with the 
hypersensitive site 2 (HS2) of the locus control region (LCR), (HS2-βp), is depicted in 
Figure 1. Briefly, the plasmid scAAV-CBAp-EGFP was used as the vector for all the 
double-stranded constructs. scAAV-CBAp-EGFP plasmid was first linealized  with 
Acc65I  followed by  filling in of the 5’-overhang with Klenow fragment of Eschelichia 
coli DNA polymerase I. The vector was then digested with AgeI to remove the chicken 
β-actin promoter. The AgeI site was filled in for construction of scAAV-HS2-βp-EGFP 
and dephosphorylated using Antarctic Phosphatase (New England Biolabs, Ipswich, 
MA).  The promoter inserts were obtained as follows: plasmid pB19p6EGFP was 
digested with BsrBI and AgeI to isolate the pB19p6 promoter and plasmid ssHS23-βp-
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β87+-globin (DB3) was digested with XhoI and NcoI and both ends blunted to obtain the 
β-globin promoter with the HS2 enhancer. All digested fragments were run on a 0.7% 
agarose gel and purified using the QIAquick
 TM 
gel extraction kit (Qiagen, Valencia, CA) 
as per the manufacturer’s instructions. The respective plasmids were ligated using T4 
ligase (New England Biolabs, Ipswich, MA) at 16ºC overnight. The ligation mixture was 
purified by butanol precipitation and used to transform Sure cells (Stratagene, La Jolla, 
CA) by electroporation at 2500 Volts, 25µF, 200 Ohms and then streaked on agar plates 
containing ampicillin.  Several plasmids containing the respective promoters were 
identified rescued as described below. These plasmids were used to generate recombinant 
enhanced green fluorescent protein (EGFP)-AAV virions, scAAV-B19p6-EGFP and 
scAAV-HS2- βp-EGFP at the Vector Core, Powell Gene Therapy Center, University of 
Florida, Gainesville, FL.  
 The overall strategy for the construction of  the self-complementary AAV 
genomes containing the β-globin gene under the control of  the β-globin promoter 
[scAAV2-βp-β87+-globin (Figure 7)], β-globin promoter with the hypersensitivity site 2 
(HS2) of the locus control region [scAAV2-HS2-βp-β87+-globin (Figure 8A)],  and the 
parvovirus B19p6 promoter [scAAV2-B19p6-β87+-globin (Figure 8B)]  is as follows. 
Plasmid HPV 436 was kindly provided by Philippe Leboulch (Harvard University). 
Plasmid DB3 (Figure 2) was constructed by inserting the globin gene and the HS2 and 
HS3 enhancer elements from HPV 436 (XbaI-XhoI) into pXS65/D10 (EcoRV).  A two-
step cloning procedure was employed when cloning plasmid ds-βp-β87+-globin. First, 
plasmid PBSK
+
-β87+-globin-I (Figure 3A) was generated by cloning the first ½ of globin 
gene (globin-1) from DB3 into plasmid pBluescript SK+ (Stratagene, La Jolla, CA) 
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following digestion of both plasmid with restriction enzymes EcoRI and BamHI.   
Secondly, plasmid PBSK+βp-β87+-globin I+2 (Figure 3B), which contained the β-globin 
promoter and the proximal ½ of the globin gene was cloned by PCR amplification from 
DB3 using the following pair of primers: forward primer; 5’-
GCACTGGTGGGGTGAATTCTTTGCCAA- 3’ and reverse primer; 5’-
CCATCGATACCACCTGACTAAAACTCC- 3’.  A ClaI site was created in the PCR 
product using the reverse primer. The PCR product was cloned into plasmid PBSK+-
β87+-globin-I following digestion of both plasmids with restriction enzymes ClaI and 
EcoRI.  Plasmid scAAV-βp-β87+-globin which contained the entire the  β-globin  
promoter and β-globin gene was generated by cloning the Acc65I and XbaI fragments 
from plasmid PBSK+-βp-β87+-globin I+2 into plasmid scAAV-CBAp-EGFP (Acc65I+ 
BbsI). The XbaI and BbsI sites were filled in with Klenow prior to digestion with 
Acc65I, allowing for a sticky end ligation at this site. For the construction of ds-HS2-βp-
β87+-globin, the HS2 enhancer and the β-globin promoter (HS2βp) were cloned from 
DB3 into scAAV-βp-β87+-globin following digestion of both plasmids with restriction 
enzymes XhoI and NcoI. Plasmid scAAV-B19p6-β87+-globin (Figure 8B) was 
constructed following ligation of the B19p6 promoter (EcoRI [filled in] + NcoI) from 
pB19p6EGFP into scAAV-βp-β87+-globin (HincII + NcoI). Plasmid PBSK+ HS234-βp-
β87+-globin (Figure 4) was constructed by inserting the entire LCR cassette and βp 
(HS234βp) into plasmid PBSK+-βp-β87+-globin I+2 following digestion of both 
plasmids with restriction enzymes Acc65I and NcoI. Plasmid ssAAV-HS234-βp-β87+-
globin (Figure 5) was constructed by inserting the Acc65I and XbaI fragment of plasmid 
PBSK+-HS234-βp-β87+-globin into the ITR containing XbaI fragment of plasmid 
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psub201. Plasmids scAAV-HS234 and scAAV-HS432 (Figure 6) were constructed by 
inserting the HS234 cassette (Acc65I and AvrII) from plasmid HPV 436 into scAAV-
CBAp-EGFP (Acc65I+ BbsI). All restriction sites were filled in which allowed the 
construction of scAAV-LCR into 2 different orientations. scAAV-HS234 is in closed-to-
open orientation while scAAV-HS432 is in open-to-closed orientation. These plasmids 
were rescued and used to generate self-complementary and conventional  AAV β87+-
globin virions - scAAV-βp-β87+-globin, scAAV-HS2-βp-β87+-globin, scAAV-B19p6-
β87+-globin, ssAAV-HS234-βp-β87+-globin, scAAV-HS234 and scAAV-HS432 in 
several serotypes (AAV1, AAV2 and AAV7) at the University of Florida vector core, 
Gainesville, FL.  Plasmid phelper (Stratagene, La Jolla, CA)  containing adenovirus 
genes (E2A, E4 and VA RNAs) and AAV serotype plasmids ACG2 (Li et al., 1997), 
AAV1, AAV7, AAV8 and AAV10 containing AAV2 Rep and  the respective serotype 
Cap protein were used along with the recombinant AAV plasmids to produce rAAV 
virions.  
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Figure 1A: Strategy for the construction of scAAV2-HS2-βp-EGFP. ITR, inverted 
terminal repeat; mITR, mutant inverted terminal repeat; EGFP, enhanced green 
fluorescent protein; SV40pA, simian virus 40 polyadenylation signal; HS32, DNA-
hypersensitive sites 3 and 2 enhancer,  HS2, DNA-hypersensitive site 2 enhancer; βp, β-
globin promoter; CBAp, chicken beta-actin promoter; scAAV, self complementary AAV 
vector. 
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Figure 1B: Strategy for the construction of scAAV2-B19p6-EGFP.  ITR, inverted 
terminal repeat; mITR, mutant inverted terminal repeat; EGFP, enhanced green 
fluorescent protein; SV40pA, simian virus 40 polyadenylation signal; pB19p6, 
parvovirus B19 p6 promoter; CBAp, chicken beta-actin promoter; scAAV, self 
complementary AAV vector. 
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Figure 2: Strategy for the construction of ssAAV2-HS32-β p-β87+-globin vector (DB3). 
ITR, inverted terminal repeat; (A)n, β-globin polyadenylation signal;  HS4, DNA-
hypersensitive site 4 enhancer; HS3, DNA-hypersensitive site 3 enhancer;  HS2, DNA-
hypersensitive site 2 enhancer; βp, β-globin promoter; p5, wt-AAV2 promoter.  
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Figure 3A: Strategy for the construction of pBluescript SK
+
-β87+-globin 1 vector. ITR, 
inverted terminal repeat; (A)n, β-globin polyadenylation signal; HS32, DNA-
hypersensitive site 3 and 2 enhancers; βp, β-globin promoter; pBSK+, pBluescript SK+ 
plasmid; mcs, multiple cloning sites. 
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Figure 3B: Strategy for the construction of pBluescript SK
+
-βp-β87+-globin 1+2 vector. 
ITR, inverted terminal repeat; (Α)n, β-globin polyadenylation signal;  HS32, DNA-
hypersensitive site 3 and 2 enhancers; βp, β-globin promoter; pBSK+, pBluescript SK+ 
plasmid; mcs, multiple cloning sites. 
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Figure 4: Strategy for the construction of pBluescript SK
+
- HS432-βp-β87+-globin 
vector. ITR, inverted terminal repeat; mITR, mutant inverted terminal repeat; (A)n,  β-
globin polyadenylation signal;  βp, β-globin promoter; scAAV, self-complementary 
AAV; HS2, DNA-hypersensitive site 2 enhancer; HS3, DNA-hypersensitive site 3 
enhancer; HS4, DNA-hypersensitive site 4 enhancer.  
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Figure 5: Strategy for the construction of ssAAV-HS234-βp-β87+-globin vector. ITR, 
inverted terminal repeat; (A)n, β-globin polyadenylation signal; βp, β-globin promoter; 
HS2, DNA-hypersensitive site 2 enhancer; HS3, DNA-hypersensitive site 3 enhancer; 
HS4, DNA-hypersensitive site 4 enhancer; p5, wt-AAV2 promoter.  
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Figure 6: Strategy for the construction of scAAV2-HS234 and scAAV2-HS432 vectors.  
ITR, inverted terminal repeat; mITR, mutant inverted terminal repeat; (A)n, β-globin 
polyadenylation signal;  βp, β-globin promoter; CBAp, chicken beta-actin promoter; 
EGFP, enhanced green fluorescent protein; SV40pA, simian virus 40 polyadenylation 
signal; scAAV2, self-complementary AAV2; HS2, DNA-hypersensitive site 2 enhancer; 
HS3, DNA-hypersensitive site 3 enhancer; HS4, DNA-hypersensitive site 4 enhancer. 
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Figure 7: Strategy for the construction of scAAV-βp-β87+-globin vector. ITR, inverted 
terminal repeat; mITR, mutant inverted terminal repeat; (A)n, β-globin polyadenylation 
signal;  βp, β-globin promoter; CBAp, chicken beta-actin promoter; SV40pA, simian 
virus 40 polyadenylation signal; scAAV, self-complementary AAV vector.  
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Figure 8A: Strategy for the construction of scAAV-HS2-βp-β87+-globin vector. ITR, 
inverted terminal repeat; mITR, mutant inverted terminal repeat; SV40pA, simian virus 
40 polyadenylation signal; (A)n, β-globin polyadenylation signal; βp, β-globin promoter; 
scAAV, self complementary AAV vector; HS32, DNA-hypersensitive site 3 and 2 
enhancers;  HS2, DNA-hypersensitive site 2 enhancer. 
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Figure 8B: Strategy for the construction of scAAV-B19p6-β87+-globin vector. ITR, 
inverted terminal repeat; mITR, mutant inverted terminal repeat; SV40pA, simian virus 
40 polyadenylation signal; (A)n, β-globin polyadenylation signal; βp, β-globin promoter; 
scAAV, self complementary AAV vector; HS32, DNA-hypersensitive site 3 and 2 
enhancers;  HS2, DNA-hypersensitive site 2 enhancer. 
 
 
 
 
C. Large scale plasmid DNA preparations 
 Large scale DNA was prepared by alkaline lysis method and purified using CsCl-
ethidium bromide density gradients (Sambrook J et al., 2001). 
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D. Preparation and purification of recombinant AAV vectors 
 AAV serotype vectors were packaged as previously described (Zolotukhin et al., 
2002). One day before transfection, confluent 293 cells in a Nunc cell factory system [Cat 
# 164327] (Nunc, Rochester, NY)  were washed once with 500 ml of sterile phosphate 
buffered saline (PBS) and treated with 500 ml of PBS containing 5mM  EDTA for about 
3-5 minutes at room temperature with gentle shaking to detach the cells from the plate 
surface. The dissociated cells were poured into a sterile 1L bottle containing 
approximately 500 ml of DMEM supplemented with 5% fetal calf serum and antibiotics 
(complete-DMEM).  5 x 10
8
-1 x 10
9
 cells were seeded in a Nunc cell factory. The 
DNA/CaCl2 precipitate was formed by addition of the molar amounts of the rAAV 
plasmid, phelper and the respective serotype plasmid (in a total plasmid concentration of 
2.5 mg/ cell factory) to 50 ml of 0.25M CaCl2.  50 ml of 2x HBS buffer (1.5 mM 
Na2HPO4, 280mM NaCl, 50mM HEPES, pH 7.05)  was added to the DNA/CaCl2  
precipitate and  incubated at RT for 1-2 minutes followed by addition of 1100 ml of 
complete-DMEM. The conditioned medium in the cell factory was exchanged with the 
CaPO4 precipitate-containing medium followed by incubation of the cells for 60-72 hrs at 
37ºC in 5% CO2. At the end of the incubation, the cells were harvested as follows. The 
conditioned media was discarded and the cells washed in 500 ml of PBS. The cells were 
dissociated from the plate by addition of 500 ml of PBS containing 5 mM EDTA for 
about 3-5 minutes at room temperature with gentle shaking, to detach the cells from the 
plate surface. The dissociated cells were poured into a sterile 500 ml centrifuge tube 
(Corning, Cat # 431123) and centrifuged at 2000 rpm for 10 min in a Beckman GPKR 
centrifuge (GH.7 rotor). The cell pellet was resuspended in 60 ml of lysis buffer (150 
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mM NaCl, 50 mM Tris, pH 8.5) and aliquoted into 4 sterile 50 ml conical polypropylene 
centrifuge tubes (Sarstedt) and subjected to 3 cycles of freezing  in dry-ice-ethanol bath 
for 10 min and thawing in a 37
o
C water bath for 10 min, with vortexing after each thaw. 
The cell lysate was subjected to benzonase digestion using 1.16 µl of benzonase (Sigma, 
St.Louis, and MO) and 3 µl of 4.82 M MgCl2 per 15 ml of cell lysate and incubated for 
30 min at 37
o
C. The cell lysate was cleared by centrifugation at 3700 rpm for 20 min at 
4
o
C and transferred into Beckman ultracentrifuge tubes (Cat # 342414). The virus was 
purified by discontinuous iodixanol step gradients prepared as described here. Iodixanol 
gradients of 40%, 25% and 15% were made from the 60% (w/v) OptiPrep (Nycomed)  
stock solution diluted in PBS-MK buffer (1X PBS, 1 mM MgCl2, 2.5 mM KCl). 1M NaCl 
was also added to the 15% density solution. The discontinuous iodixanol step gradients 
was made from the bottom to top with 5 ml of 60%, 7.5 ml of 40%, 5 ml of 25%, 7.5 ml 
of 15% iodixanol and 15 ml of cell lysate and centrifuged in a Beckman 70 Ti rotor at 
69,000 rpm for 1hr at 18
o
C. The virus-containing 40-60% interface was collected using 
an 18-gauge needle connected to a syringe and subjected to further purification by 
column chromatography. For AAV2 purification, 5 ml  HiTrap SP column (Amersham 
Biosciences) was  equilibrated using a Pharmacia P-1 peristalsis pump (Pharmacia) with 
12 ml buffer A (0.3X PBS),  25 ml buffer B (0.3X PBS + 1 M NaCl)  and 50 ml buffer A 
at a flow rate of 5 ml/min. The virus/iodixanol fraction was diluted in buffer A at 1:1 
ratio, loaded onto the column, and washed with 50 ml of buffer A. The virus was then 
eluted in 20 ml of Buffer C (0.3X PBS, 350 mM NaCl) and buffer exchanged with 10 ml 
of Lactated Ringers (Abbott Laboratories)  in a  20 ml  Apollo centrifugal spin 
concentrator (Cat # AP2015010) and centrifuged at 3000 rpm at 6 min. The sample was 
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buffer exchanged a second time using 25 ml of Lactated Ringers and concentrated to a 
final volume of 0.5 ml. For AAV serotype 1, 7, 8 and 10, a 5 ml HiTrap Q column 
(Amersham Biosciences) was equilibrated in buffer A (20 mM Tris, 15 mM NaCl, pH 
8.5), buffer B (20 mM Tris, 1M NaCl, pH 8.5) and buffer A. The sample was eluted in 
buffer C (20 mM Tris, 350 mM NaCl, pH 8.5) buffer exchanged in LR and concentrated 
to 0.5 ml as described for AAV2 above.  100 µl virus-containing aliquots were 
distributed into siliconized/low retention microcentrifuge tubes (Fisher Scientific) and 
stored in -80
o
C. 
 
E. Quantitative DNA slot blot analysis 
 Viral titers were quantified by DNA slot blot analysis as previously described 
(Kube et al., 1997; Samulski et al., 1989; Srivastava et al., 1989).  Briefly, 1µl and 10 µl 
of AAV particles and a 1 µg and 10 µg of a plasmid standard, containing the packaged 
transgene were disrupted and denatured in 100mM NaOH at 65ºC for 30-60 min in a total 
volume of 100 µl. The samples and standards were then chilled on ice for 5 min and 
pulsed down prior to the addition of 100µl of 20X SSC (3M NaCl, 0.3 M sodium citrate, 
pH 7.0) and 2µl of loading dye. The sample was mixed and loaded onto Immobilon 
NY+
TM
 membranes (Millipore, Bedford, MA) using a Bio Dot SF vacuum manifold 
(Bio-Rad, Hercules, CA) in a two-fold serial dilution. The membranes were cross-linked 
with UV Stratalinker (Stratagene, La Jolla, CA) and prehybridized for 2hrs in a roller 
bottle containing 20 ml hybridization solution containing 6x SSC, 0.5% sodium dodecyl 
sulphate (SDS), 100 µg/ml freshly boiled herring sperm DNA and 5x Denhardt’s reagent 
[1% ficoll, type 400 (Pharmacia), 1% polyvinypyrrolidone (Kodak), 1% bovine serum 
albumin (BSA) (Sigma)]. To hybridize the membrane, a 
32
P-labeled DNA probe was 
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boiled for 5 min, and chilled for 5 min before being added to the hybridization solution, 
and incubated for 16-20 hrs at 68ºC.  The membrane was then washed in 2x SSC, 0.1% 
SDS for 5 min at room temperature followed by three 15 min wash cycles in 2L of 0.1x 
SSC, 0.1% SDS at 65ºC prior to being exposed to BIOMAX MR
 TM
 X-ray films (Kodak, 
Rochester, NY) at -70ºC. The films were developed and viral titers computed. 
 
F. 
32
P-labeling of DNA probes 
 DNA probes were synthesized by random priming as described by Feinberg and 
Vogelstein (Feinberg et al., 1983). The 50-100 ng of DNA fragment was purified from a 
0.7% agarose gel using the QIAquick
TM 
gel extraction kit (Qiagen, Valencia, CA) as per 
manufacturer’s instructions and resuspended in 30 µl of ddH2O. To denature the 
template, approximately 10 µl of oligonucleotide buffer [1M HEPES,pH 6.6 250 mM 
Tris-HCl, pH 8.0, 52 mM β-mercaptoethanol, 0.1mM dATP, 0.1mM dTTP, 0.1 mM 
dGTP, 27 U/ml of random hexanucleotides] (Roche, Indianapolis, IN)  was added to the 
DNA, and the mixture was heated for 5 min at 100°C  and then rapidly chilled on ice  for  
5 min. 1 µl of BSA,  8 units of klenow (Promega, Madison, Wi) and 5 µl of α 32P-dCTP 
(10 µCi/ µl) (Amersham, Piscataway, NJ) were added to the reaction mixture and then 
incubated at 37ºC for 2 hr. Unincorporated α 32P-dCTP was removed from the 
radiolabeled-DNA fragments by spun-column chromatography through a Microspin
TM
 G-
50 Columns (Amersham, Piscataway, NJ). Cerenkov radiation was detected in 2 µl of 
probe using a liquid scintillation spectrometer. 
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G. Animal handling 
 All animal experiments were performed according to the guidelines
 
for animal 
care at the University of Florida Animal Care Services (ACS). Six weeks old C57BL/6J 
female recipient mice (stock number 000664), 6-weeks old B6.SJL-Ptprc (a) Pep3 
(b)/BoyJ donor male mice (stock number 002014) and 6-week Hba
tm1Paz
 Hbb
tm1Tow
 
Tg(HBA-HBBs) 41Paz/J (stock number 003342) donor female mice were purchased 
from Jackson Laboratory (Bar Harbor, ME) and maintained in the animal facility of the 
University of Florida College of Medicine, Gainesville, FL.  The Institutional Animal 
Care and Use Committee approved all protocols for the care and handling of mice. 
 
H. Isolation of murine Scal
+
, c
-
Kit
+
, lin
-
 cells 
 Following inhalation of anesthesia, donor mice were sacrificed by cervical 
dislocation and the femur and tibia removed using a pair of scissors. Muscles were 
removed from the bones using a pair of scissors and paper towels. A small cut was made 
at the distal aspects of the femur and tibia and bone marrow collected into sterile 15 ml 
conical tubes (Sarstedt) by flushing with 1 ml of PBS using a ½ cc U-100 insulin syringe 
(Becton Dickinson). The cells were pelleted at 1100 rpm for 5 min at 4ºC, followed by 
lyses of red blood cells (RBC) using 0.5 ml of ACK lysis buffer (0.15 M NH4Cl, 10 mM 
KHCO3, 0.1mM Na2EDTA, pH 7.2-7.4) per animal at room temp for 5 min. PBS was 
immediately added to a final volume of 14 ml, and cells were centrifuged at 1,100 rpm 
for 5 min at 4ºC and counted. Cells were resuspended in PBS containing 10% fetal 
bovine serum (FBS) at a cell count of 5 x 10
7
 cells/ml.  Lineage antibody cocktail 
(specific for antigens expressed by erythroid, myeloid, and lymphoid lineages) was added 
at a dilution of 1:10 and cells incubated on ice for 20 min.  Cells were washed using 10 
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ml PBS+10% FBS and centrifuged at 1,100 rpm for 5 min at 4ºC. Cells were resuspended 
in 1 ml PBS+10%FBS. Lineage-positive cells were separated from lineage-negative by 
immuno-magnetic beads (sheep anti-rat specific; Dynal, Great Neck, NY) columns.  The 
depletion process was repeated, and lineage-negative cells were resuspended at a cell 
count of 2 x 10
6
 cells/100µl of PBS+10% FBS. Phycoerythrin-conjugated anti-Sca-1 (Ly-
6A/E), and allophycocyanin-conjugate (APC) anti-c-kit (BD Bioscience) was added at 
1:200 dilutions and incubated on ice for 20 min.  Cells were washed and suspended in 2 
ml PBS+10% FBS, filtered through nylon filter, and sorted using a Becton Dickinson 
Vantage Fluorescence-Activated Cell Sorter (FACS).  Sca-1
+
, c-kit
+
, lin
-
 cells were 
collected in PBS+10% FBS. 
 
I. Analysis of AAV2 receptor and co-receptor expression 
 Primary murine HSCs were prepared as described above and sent for sorting by 
FACS at the Indiana University Flow Cytometry core. Sca1
+
, c-kit
+
, lin
-
 cells were then 
stained with HSPG-phycoerythrin conjugated antibody (HSPG-PE) and Fc-FGF antibody 
for 20 min  and washed 3x with PBS/10% FBS. Secondary staining with an anti-Fc-APC 
antibody was then performed. Cells were washed 3x in PBS/10% FBS and analyzed by 
flow cytometry using a FACS caliber machine. 10
5
 events were recorded.  
 
J. Recombinant AAV transduction assays 
 Equivalent numbers of K562 cells were washed once in serum-free IMDM and 
either mock infected or infected with rAAV vectors containing the EGFP gene or  the 
anti-sickling β-globin gene (β87+) with 2 x 104 particles/cell at 37ºC for 2 hrs 
(Ponnazhagan et al., 1994). The cells were incubated for 72 hrs following the addition of 
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complete-IMDM. Transgene expression was evaluated by flow cytometry and reverse-
transcription PCR (RT-PCR) as described below. 
 For 7-day transduction assays, mouse bone marrow c-kit
+
, lin
-
 hematopoietic cells 
were obtained as described above and infected with 5 x 10
4 
particles/cell at 37ºC for 2 
hrs. The cells were incubated for 7 days following the addition of complete IMDM 
supplemented with IL-3 (10 ng/ml), IL-6 (10 ng/ml), stem cell factor (SCF) (1ng/ml) and 
erythropoietin (EPO) (5U/ml) and transgene expression was evaluated by flow cytometry 
using a FACS caliber machine. 
 For long  term transduction assays, approximately 10,000 double positive (Sca1
+
, 
c-kit
+
, lin
-
) or 20,000- 50,000 single positive (c-kit
+
, lin
-
) cells per mouse were infected 
with the recombinant AAV vector at 5 x 10
4 
-1 x 10
5
 
 
particles/cell in serum-free IMDM 
at 37ºC for 2 hrs with mixing every 15 min. The cells were washed in PBS and injected 
into the retro-orbital sinus of lethally irradiated C57/BL/6J (CD45.2) mice. 5-6 mice were 
used for each virus and transgene expression evaluated 3-6 months post transduction. 
 
K. Bone marrow transplantations 
 Six weeks-old recipient mice were irradiated
 
with 950 cGy from a cesium
137
 
source and transferred to clean cages. The recipient mice were anesthetized with 
isofluorane and injected retro-orbitally with mock-transduced or vector-transduced cells 
suspended in 100 µl PBS.  The mice were maintained on water treated with 
trimethoprim/sulfasoxazole
 
for 2 weeks after transplantation.  
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L. Fluorescence-activated cell sorter (FACS) analysis 
 Mock and EGFP- vector transduced K562 cells were washed in PBS and analyzed 
on a FACsort machine (BD Biosciences, San Jose, CA) at the University of Florida Flow 
Cytometry Core. 10
5 
events were recorded. For analysis of β-globin expression, mock 
and (β87+) vector-transduced K562 cells and mouse bone marrow c-kit+, lin- 
hematopoietic cells were fixed with 4% paraformaldehyde, washed in PBS and 
permeabilized with 100% ice-cold methanol as per manufacturer’s instructions (Santa 
Cruz Biotechnology, Inc, CA). The cells were washed in PBS and stained intracellularly 
with PE-conjugated mouse anti-human  β-globin antibody (Santa Cruz Biotechnology, 
Inc, CA)  at 1:100 dilution for 10
6 
cells in 100 µl of FCM wash buffer. Human β-globin 
protein was detected by flow cytometry on a FACsort machine (BD Biosciences, San 
Jose, CA) at the University of Florida Flow Cytometry Core. 10
5 
events were recorded.  
 For multilineage analysis of scAAV mediated EGFP expression, bone marrow 
cells from mice 3-6 months post-transplantation were harvested as described above and 
equal aliquots stained separately using phycoerythrin (PE)-conjugated lineage specific rat 
anti-mouse mAbs. Rat anti-mouse B220 was used for B lymphocytes; anti-CD4 &anti-
CD8a for T lymphocytes and anti-Gr-1 for myeloid cells. For analysis of erythroid cell 
lineage, dual staining with rat anti-mouse c-kit
+
-PE and CD71- PE-Cy5 for early 
erythroblasts, and CD71- PE-Cy5 +Ter119-PE for late erythroblasts and mature RBCs 
was performed. Cells were incubated on ice for 20 min, washed in PBS/10% FBS and 
analyzed on a FACsort machine. 1-3 x 10
5 
events were recorded. 
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M. Southern blot analysis for AAV integration 
 Total genomic DNA was isolated from bone marrow cells from secondary 
transplant recipient mice 3-months post- transplantation.  Briefly, red blood cells (RBC) 
were lysed using 0.5 ml/mouse of ACK lysis buffer at room temperature for 5 min. PBS 
was added immediately and cells were centrifuged at 1,100 rpm for 5 min at 4ºC.  Cells 
were lysed using a genomic DNA lysis buffer (10 mM Tris [pH 8], 1 mM EDTA, 200 
mM NaCl, 0.5% sodium dodecyl sulfate, 200 µg of proteinase K per ml) at 37ºC 
overnight.  The samples were extracted with phenol and chloroform, and precipitated 
with 2 volumes of ethanol overnight at -20ºC.  The DNA was pelleted at 4ºC for 30 min, 
washed with 70% ethanol, and air-dried briefly.  The DNA was resuspended in 500 µl of 
TE (10 mM Tris [pH 8], 1 mM EDTA), digested with 10 µg of RNase A (Sigma, St. 
Louis, Mo.) at 37ºC for 3 hrs, extracted with phenol and chloroform, and precipitated 
with ethanol at -20ºC. Each pellet was resuspended in 200 µl of TE. Twenty micrograms 
of DNA samples were digested with restriction endonucleases that cleave the proviral 
genome once (NcoI), or cleave twice (NcoI + HindIII), and electrophoresed on 1% 
agarose gels followed by Southern blot hybridization with a 
32
P-labeled EGFP-specific 
DNA probe.  
 
N. Morphological analysis of peripheral blood and bone marrow cells 
 Peripheral blood and bone marrow samples from mice transplanted with mock-
transduced or scAAV vector-transduced HSCs were reviewed by the Molecular 
Pathology Core in the Department of Pathology at the University of Florida. These cells 
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were stained with hematoxylin–eosin (H&E), and visualized under a light microscope at 
a magnification of x400.  
 
O. RT-PCR for β-globin transgene expression 
 RNA was isolated using Invitrogen RNA isolation kit as per manufacturer’s 
instructions (Invitrogen, Carlsbad, CA) and subjected to a two-step RT-PCR procedure 
(MyiQ Single-Color Real-Time PCR Detection System, BIO-RAD, Hercules, CA). First 
the RNA was run on a 1.2% agarose gel made using DEPC treated 1X TBE buffer to 
determine its quality. The RNA was reverse-transcribed using iScript 
TM
 cDNA Synthesis 
kit and the cDNA was then amplified using iQ 
TM
 SYBR® Green supermix  as per 
manufacturer’s instructions (both kits were purchased from BIO-RAD, Hercules, CA). A 
three step PCR procedure was performed as follows: Step 1 (95
o
C for 5 min, 95
ο
C for 30 
min), step 2 (55
o
C for 1 hr), Step 3 (72
o
C for 30 min). Primer sets common to both 
endogenous and vector-derived β-globin transcripts (Common A: 5’-
CGAGGAGAAGTCCGCCGTTACTG-3', and Common B: 
5’CACTTTCTGATAGGCAGCCTGCACT-3’) and unique to vector-derived β-globin 
transcript (Mutant A: 5’-GAGAAGTCCGCCGTTACTGTT-3, and Mutant B: 5’-
GAAGTTCTCAGGATCCACGT-3’) were used as previously described (Oh et al., 
2004).  Half of the PCR product was digested with PvuII and electrophoresed on 1.5% 
agarose gel followed by southern blot analysis using a 
32
P-labeled β-globin DNA probe. 
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P. Analysis of globin expression in sickle cell disease mice 
 Peripheral blood was drawn from the retroorbital sinus of mock and vector treated 
donor recipient mice 3 months post-transplant using heparin treated glass tubes and place 
in EDTA treated Eppendorf tubes and then shipped on ice to the laboratory of Dr. Ching-
Nan Ou at Texas Children's Hospital, Texas who performed the HPLC, globin chain, and 
isoelectric focusing (IEF) analyses.  
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RESULTS 
A. Expression of AAV2 receptor and co-receptor   
 AAV2 uses cell surface heparan sulfate proteoglycan (HSPG) as a receptor, and 
fibroblast growth factor receptor 1 (FGFR1) or αvβ5 integrin as co-receptors. Previous 
studies in our laboratory have shown donor variability in the ability of AAV2 vectors to 
transduce human CD34
+
 cells due to the inability of the virus to bind cells that do not 
express the receptor for AAV2  (Ponnazhagan et al., 1997a). To determine whether the 
barrier to transduction of murine HSCs  was due to lack of binding and entry of AAV2 
into these cells, we studied the level of expression of HSPG and FGFR1 in primary 
murine Sca1
+
, lin
-
 cells by FACS. These results are shown in Figure 9. Although 
approximately 50% of these cells expressed HSPG and 40-60% expressed FGFR, only 
10-20% of these cells co-express the receptor and co-receptor for AAV2. These results 
indicate that viral binding and entry limits transduction of murine HSCs by AAV2 
vectors. Moreover, AAV2 failed to transduce this subset (10-20%), indicating that other 
barriers to transduction of murine HSCs do exist.  
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Figure 9: Analysis of cell surface heparan sulfate proteoglycan (HSPG) and fibroblast 
growth factor receptor (FGFR) receptor expression in primary murine Sca1+, lin- cells by 
FACS. 5 x 10
6
 low density bone marrow cells (LDBM) from C57Bl6 mice were isolated 
and stained with 1µg/10
6 
of Sca-1-PECy5, lineage-specific-FITC antibodies and i)HSPG-
PE (BD) ii) Fc-FGF fusion protein for 1hr, washed twice in PBS and stained with 
secondary anti-human Fc-APC [Fc-FGF+Fc-APC] (Leinco) and iii) both HSPG-PE and 
[Fc-FGF+Fc-APC] antibodies. Cells were washed in PBS and analyzed with a FACStar 
instrument. 10
5
 events were recorded. Experiment was repeated three times. Data shown 
is from one representative experiment. 
 
B. AAV1 serotype vector is the most efficient  in murine HSCs in liquid cultures 
in vitro 
 Since CMV-driven ssAAV2 vectors failed to efficiently transduce primary murine 
HSCs, we generated HS2-β-globin and B19p6-promoter- driven scAAV1 and scAAV7 
EGFP-vectors (Figure 10) and used then to transduce Sca1
+
, c-kit
+
, lin
-
 murine 
hematopoietic cells in 7-day liquid cultures in vitro. These results are shown in Figure 11. 
Whereas scAAV1-B19p6-EGFP transduced murine HSCs efficiently, transduction from 
all other vectors was insignificant. These results are consistent with our previous 
observation of AAV1 vector’s ability to transduce murine HSCs in short-term liquid 
cultures efficiently (Zhong et al., 2006a).  
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Figure 10: Schematic representation of conventional, single-stranded AAV2 and double-
stranded, self-complementary AAV serotype vectors.  ITR, inverted terminal repeat; 
mITR, mutant inverted terminal repeat; CMVp, cytomegalovirus immediate-early 
promoter; EGFP, enhanced green fluorescent protein; sv40pA, simian virus 40 
polyadenylation signal; HS2, DNA-hypersensitive site 2 enhancer; βp, β-globin 
promoter; ssAAV, single-stranded AAV; scAAV, self-complementary AAV. 
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Figure 11: Comparative analysis of AAV1 & AAV7 vectors containing B19p6 or HS2-
β-globin promoter-driven EGFP expression in Sca1+, c-kit+, lin- murine hematopoietic 
cells in vitro.  Equal numbers of bone marrow-derived Sca1
+
, c-kit
+
, lin
-
 cells were mock-
infected or infected with scAAV vectors at 37
o
C for 2 hrs and maintained in liquid 
culture for 7 days. Transgene expression was evaluated by flow cytometry using a 
FACStar instrument. 
 
 
C. Comparative analyses of EGFP gene expression from HS2-β-globin promoter 
or the B19p6 promoter using AAV serotype vectors in primary murine 
hematopoietic progenitor cells in vivo 
 Equal numbers of primary murine bone marrow-derived Sca1
+
, c-kit
+
, lin
-
 cells 
were mock-infected or infected with scAAV serotype 1, 2, 7, 8 and 10 vectors at 37
o
C for 
2 hrs, followed by transplantation into lethally-irradiated syngeneic recipient mice as 
described in Materials and Methods.  Erythroid-specific transgene expression was 
evaluated in bone marrow mononuclear cells 6 months post-transplantation after co-
staining with the c-kit
+
/CD71 antibodies. Since expression of c-kit
+
 is down-regulated, 
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while expression of CD71 is upregulated during erythroid development, EGFP 
expression was analyzed based on the co-expression of the above pair of receptors 
(Figure 12 and Table 1) as previously described (Socolovsky et al., 2001; Spangrude et 
al., 2006). These results are shown in Figure 13 and 14. Consistent with the published 
data (Spangrude et al., 2006), the highest level of EGFP expression was observed in the 
early intermediate erythroblast stages R2 (c-kit
+ high
, CD 71 
low
), followed by R3 (c-kit
+
 
high
, CD71 
high
) and R4 (c-kit
+
 
low
, CD71 
high
). EGFP expression in R5 was insignificant. In 
contrast to previously published data, expression in R1 (c-kit
+
 
high
, CD71 
negative
) and R6 
(c-kit
+
 
low
, CD71 
low
) was insignificant. This observation can be explained by the use of 
erythroid-specific promoters in the AAV constructs, which are inactive in the multipotent 
progenitors and lymphocyte lineage.   Analysis of EGFP expression showed progressive 
loss of fluorescent during erythroid development. The loss of EGFP fluorescence could 
be due to i) global repression of non-globin genes during development, ii) degradation of 
the EGFP protein in the erythroblasts, or iii) fluorescent quenching by hemoglobin 
(Spangrude et al., 2006).  
 Consistent with our previously published studies, the transduction efficiency of 
AAV1 vectors was higher than that of AAV2 vectors in the intermediate erythroblast 
stage (c-kit
+ high
, CD 71 
low
) as shown again in Figure 14. The transduction efficiency of 
AAV7 vectors was similar to that of AAV1, while that of AAV8 and AAV10 was similar 
to that AAV2.  It is noteworthy that up to 20% transduction by AAV2 vectors could also 
be achieved, which was due to the combined use of the double-stranded vector genomes 
and the hematopoietic cell-specific promoters.  
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  In addition, EGFP expression from the B19p6 promoter was more efficient than 
that from the HS2 enhancer/ β-globin promoter in AAV1 and AAV7 serotypes even in 
the absence of HS2 enhancer. In order to be active, the β-globin promoter requires the 
locus control enhancer element (LCR), consisting of hypersensitivity regions 1 through 5 
(HS1, HS2, HS3, HS4 and HS5), with HS2 having the highest enhancer activity.  Only 
the HS2 enhancer was included in the AAV constructs due to the size limitation of self-
complementary AAV vectors, which could have a limiting effect on the strength of the 
HS2-β-globin promoter containing vector. Although viral promoters are smaller in size, 
several studies have documented their stronger promoter activity compared to eukaryotic 
promoters (Zhong et al., 2006b, Maina et al., 2008a and b).  
 
 
 
Figure 12: Analysis of erythroid-restricted EGFP expression in primary murine 
hematopoietic progenitor cells. Gate R1 (c-kit
+
 
high
, CD71 
negative
), R2 (c-kit
+
 
high
, CD71 
low
), R3 (c-kit
+
 
high
, CD71 
high
), R4 (c-kit
+
 
low
, CD71 
high
) R5 (c-kit
+
 
negative
, CD71 
high
) and 
R6 (c-kit
+
 
low
, CD71 
low
).   
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Table 1: Gate R1 represents multipotent progenitor cells, R2-R4 represents progressive 
intermediate erythroblast stages, R5 is the basophilic erythroblast stage while R6 
represents the lymphoid lineage. 
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Figure 13: Comparative analyses of EGFP gene expression from HS2-β-globin promoter 
or the B19p6 promoter using AAV serotype vectors in primary murine hematopoietic 
progenitor cells. Equal numbers of bone marrow-derived Sca1
+
, c-kit
+
, lin
-
 cells were 
mock-infected or infected with scAAV vectors at 37
ο
C for 2 hrs followed by 
transplantation into lethally- irradiated syngeneic recipient mice. Transgene expression 
was evaluated 6 months post-transplantation by flow cytometry using a FACStar 
instrument after staining with c-kit and CD71 antibodies. Results are shown for all the 
stages of erythroid differentiation (Gate R1-R6). 
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Figure 14: Comparative analyses of EGFP gene expression from HS2-β-globin promoter 
or the B19p6 promoter using AAV serotype vectors in primary murine hematopoietic 
progenitor cells. Equal numbers of bone marrow-derived Sca1
+
, c-kit
+
, lin
-
 cells were 
mock-infected or infected with scAAV vectors at 37
ο
C for 2 hrs followed by 
transplantation into lethally- irradiated syngeneic recipient mice. Transgene expression 
was evaluated 6 months post-transplantation by flow cytometry using a FACStar 
instrument after staining with anti-c-kit and anti-CD71 antibodies. Results are shown 
only for the intermediate erythroblast stage (Gate 2). 
 
 
D. Lineage analysis of transgene expression mediated by scAAV serotype 
vectors in murine hematopoietic progenitor cells 6 months post-primary 
transplantation and 3-months post-secondary transplantation 
 To confirm the erythroid lineage restricted activity of the HS2-β-globin and the 
B19p6 promoters, we also performed lineage analysis of transgene expression mediated 
by scAAV serotype vectors in murine hematopoietic progenitor cells 6-months post-
primary transplantation using lineage specific antibodies as described in Materials and 
Methods. These results are shown in Table 2. Whereas EGFP expression was clearly 
observed in the erythroid lineage (9-35%), no significant EGFP expression was present in 
any of the other lineages tested (T lymphocytes, B lymphocytes, myeloid cells, and 
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mature RBCs). These results further confirm that expression from the HS2-β-globin and 
B19p6 promoters was erythroid restricted regardless of the serotype used. The lack of 
EGFP expression in the terminally differentiated Ter119 positive erythroid population is 
likely due to the quenching of EGFP fluorescence by globin which indicates that EGFP is 
not the ideal reporter for erythroid engraftment as previously shown (Spangrude et al., 
2006). While several previously published studies have shown the activity of B19p6 
promoter to be mainly limited to human erythroid cells undergoing differentiation 
(Kurpad et al., 1999; Wang et al., 1995b), this is the first study demonstrating that the 
activity of B19p6 promoter is also erythroid restricted in murine hematopoietic cells.   
The presence of EGFP-positive cells in the bone marrow mononuclear cells 
implied but did not confirm that a hematopoietic stem cell(s), capable of long-term bone 
marrow reconstitution, had been transduced by the scAAV vectors. To address this issue 
directly, bone marrow mononuclear cells from a scAAV7-B19p6-EGFP vector-
transduced or a mock-transduced primary recipient mouse were used to transplant four 
lethally-irradiated syngeneic mice. Three months post-secondary transplantation, bone 
marrow mononuclear cells were harvested and analyzed for transgene expression in 
lymphoid, myeloid, and erythroid lineages as previously described. These results are 
shown in Table 3.  Consistent with the primary transplantation results, erythroid lineage-
restricted expression in up to 30% of erythroid cells was readily detectable, 9-months 
post-transplantation, suggesting that a primitive stem cell(s), capable of long-term 
reconstitution, had indeed been transduced.   
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Table 2: Bone marrow cells were incubated with phycoerythrin (PE)-conjugated lineage 
specific rat anti-mouse mAbs (anti-B220 for B lymphocytes; anti-CD4 & anti-CD8a for T 
lymphocytes; anti-Gr-1 for myeloid cells; and anti-Ter119 for mature RBCs) separately 
and analyzed for GFP expression by flow cytometry using a FACsort machine. 
Erythroblasts were stained with anti-c-kit and anti-CD71. 
 
 
 
Table 3: Bone marrow cells from a scAAV7-B19p6-EGFP vector-transduced primary 
recipient mouse were used to transplant 4 lethally-irradiated syngeneic mice. Three 
months post-secondary transplantation, bone marrow cells were harvested and incubated 
with phycoerythrin (PE)-conjugated lineage specific rat anti-mouse mAbs (anti-B220 for 
B lymphocytes; anti-CD4 & anti-CD8a for T lymphocytes; anti-Gr-1 for myeloid cells; 
and anti-Ter119 for mature RBCs) separately and analyzed for EGFP expression by flow 
cytometry using a FACsort machine. Erythroblasts were stained with anti-c-kit-PE and 
anti-CD71-PECy5. 
 
 64 
E. Southern blot analysis for integration of the proviral AAV-EGFP genome in 
murine hematopoietic progenitor cells 3-months post-secondary 
transplantation 
 In order to determine whether the proviral AAV genomes were stably integrated 
within the host chromosomal DNA, total genomic DNA was isolated from bone marrow 
mononuclear cells from mock-transduced and three secondary transplant recipient mice.  
Equivalent amounts of total genomic DNA were digested with restriction enzymes that 
cleave within the recombinant genome once (NcoI), or twice (NcoI+HindIII) and 
analyzed by southern blot analysis using an EGFP DNA as a probe. These results are 
shown in Figure 15.  Following digestion with NcoI, no hybridization signal was detected 
in the mock transduced mice, while unique bands were detected in the three vector 
transduced mice. In addition, following digestion with NcoI + HindIII, the predicted 0.9 
kb band was detected from DNA samples from each transplanted mouse. The distinct 
band pattern following digestion with NcoI and NcoI+ HindIII suggest random 
integration. These data are consistent with the interpretation that the AAV proviral 
genomes are stably integrated into the host cell chromosomal DNA, and further 
corroborate our previously published studies (Han et al., 2008; Tan et al., 2001b; Zhong 
et al., 2006a). 
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Figure 15: Southern blot analysis for integration of the proviral AAV2-EGFP genome in 
murine hematopoietic progenitor cells 3 months post-secondary transplantation. 
Equivalent amounts of total genomic DNA from bone marrow nuclear cells from 
secondary recipient mice following bone marrow transplantation with mock-transduced 
or scAAV7-B19p6-EGFP vector-transduced primary murine HSCs were digested with 
NcoI (one site in the vector genome), or with NcoI+HindIII (two sites in the vector 
genome), electrophoresed on agarose gels, and probed with an EGFP-specific DNA 
probe. The arrow indicates the 743-bp expected size fragment from the EGFP transgene. 
 
 
F. Morphological analysis of peripheral blood and bone marrow cells following 
transplantation with scAAV serotype vector-transduced primary murine 
hematopoietic stem cells 
 A recently published report of the development of hepatocellular carcinoma  in 
mice injected as neonates with AAV vectors has raised safely concerns (Donsante et al., 
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2007). To determine whether stable integration of AAV sequences led to any toxicity in 
hematopoietic tissues, peripheral blood and bone marrow samples from primary 
recipients 6 months post-transplantation were reviewed by the Molecular Pathology Core 
in the Department of Pathology at the University of Florida and the results are shown in 
Figure 16. Analysis of the hematopoietic tissues from mock-, scAAV-HS2-βp-EGFP- 
and scAAV-B19p6-EGFP- vector transduced mice showed no deleterious effects of AAV 
integration in this study or in a previous study from our lab with a larger cohort (Han et 
al., 2008). 
 
 
 
Figure 16: Morphological analysis of peripheral blood and bone marrow cells following 
transplantation with scAAV serotype vector-transduced primary murine hematopoietic 
stem cells. Peripheral blood and bone marrow samples from mice transplanted with 
mock-transduced or the indicated scAAV vector-transduced HSCs were stained with 
hematoxylin-eosin (HE), and visualized under a light microscope. X400. 
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G. Self-complementary AAV-β87+-globin vectors containing only the HS2 
enhancer element are more efficient than their single-stranded counterpart 
containing HS2 HS3 HS4 enhancers 
 We first wished to determine whether scAAV vectors, which bypass the rate-
limiting step of viral second-strand synthesis, are more efficient in transducing a human 
erythroleukemia cell line, K562, which does not express the endogenous β-globin gene 
(Lozzio et al., 1979). Equivalent numbers of K562 cells were infected with a 
conventional, single-stranded AAV vector containing the entire locus control region 
cassette (ssAAV2-HS234-βp-β87+-globin; Figure 17A, i) and an scAAV vector 
containing only the HS2 enhancer (scAAV2-HS2-βp- β87+-globin; Figure 17A, ii) at 2 x 
10
4
 vector particles/cell at 37ºC for 2 hr. Transgene expression analyses were performed 
by RT-PCR 72 hr post-infection, using primers that were common to endogenous and 
vector derived-globin transcripts (Pr. comA and Pr. comB; Figure 17B) as previously 
described (Oh et al., 2004). Restriction digestion with Pvu II was also used to 
discriminate between endogenous and vector-derived β87+-globin transcripts. These 
results are shown in Figure 17C.  As can be seen, when the common set of primers was 
used, the expected 384-bp band could be cleaved with Pvu II, yielding the expected 244- 
and 140-bp products only in vector-transduced, not in mock-transduced cells. Although 
K562 cells do not express the endogenous β-globin gene (Lozzio et al., 1979), they do 
express 13% of the endogenous δ-globin gene (Poddie et al., 2003). The 384-bp fragment 
in mock-transduced cells was generated only when common primers were used, which 
amplify the endogenous β-globin gene, but not when mutant primers specific for the β87+ 
-globin gene were used, which do not amplify the endogenous β-globin gene (see below). 
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No product was obtained after amplification in the absence of reverse transcriptase (RT), 
or in the negative control sample. Densitometric scanning and quantitation of these data 
(Figure 17D) indicated that although the scAAV vector contained only one enhancer 
element (HS2), expression from this vector was 3-fold higher than that from the ssAAV 
vector, which contained all three enhancers (HS2+HS3+HS4). These results corroborate 
that viral second-strand DNA synthesis is a rate-limiting step in the transduction of K562 
cells with conventional ssAAV2 vectors. Previous studies in our laboratory have 
documented that the phosphorylated form of FKBP52 is predominant in K562 cells, and 
is responsible for the low recombinant AAV2-mediated transgene expression in this cell 
type (Qing et al., 1998). Thus, although the scAAV2 vector contained only one enhancer 
element, it was able to lead to efficient transduction of K562 cells. 
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Figure 17: A) Schematic structures of the single-stranded (ssAAV2-HS432-βp-β87+-
globin, i), and self-complementary (scAAV2-HS2-βp-β87+-globin, ii) vectors. B) 
Nucleotide sequence alignment of relevant codons of the endogenous β-globin and the 
anti-sickling β87+-globin genes. The schematic structure of the β-globin cDNA, relative 
positions of the common primers (Pr. comA and Pr. comB), and the expected sizes of 
DNA products, with and without Pvu II digestions, are also indicated. C) Comparative 
analysis of scAAV2-HS2-βp-β87+-globin and ssAAV2-HS432-βpβ87+-globin vector-
mediated β-globin gene expression in K562 cells. Equivalent numbers of cells were 
either mock-infected (Mock) or infected with recombinant vectors under identical 
conditions. Total RNA samples were subjected to a two-step RT-PCR procedure using 
the common primers. Half of the samples were digested with Pvu II and electrophoresed 
on agarose gels followed by Southern blotting and hybridization using a β-globin-specific 
DNA probe. U: undigested, D: digested with Pvu II, RT: reverse transcriptase. D) 
Densitometric scanning of autoradiographs for the quantification of relative amounts of 
the PCR products. 
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H. scAAV-β87+-globin vectors and scAAV-HS234 vectors recombine and lead 
to β-globin expression after dual vector transduction. 
 Because optimal expression of the β-globin gene requires the entire enhancer 
element (HS2+HS3+HS4), and because the packaging capacity of scAAV vector 
precludes such a possibility, we sought to take advantage of the dual-vector approach, 
which has been shown by a number of investigators to enhance AAV-mediated gene 
expression through intermolecular recombination (Duan et al., 2000) (Chao et al., 2002) 
(Duan et al., 2001; Nakai et al., 2000; Sun et al., 2000; Yan et al., 2000) (Yan et al., 
2002a) (Reich et al., 2003; Xu et al., 2004) (Ghosh et al., 2006; Ghosh et al., 2008; Lai et 
al., 2006; Yan et al., 2005). In this strategy, a single gene is split into two separate 
scAAV vectors, which then undergo intermolecular recombination after cellular entry 
and viral uncoating. We therefore constructed the following three vectors: scAAV2- βp-
β87+-globin (Figure 18A, i); scAAV2-HS2+HS3+HS4 Figure 21A, ii), in a closed-to-
closed (C-C) orientation of the AAV inverted terminal repeats (ITRs) relative to the 
scAAV2-βp-β87+-globin vector; and scAAV2-HS4+HS3+HS2 (Figure 18A, iii) in a 
closed-to-open (C-O) orientation. Each scAAV genome contains a closed (C) and an 
open (O) end structure of the ITR, and these orientations refer to the two possible 
alignments, as described previously (Choi et al., 2005). These vectors were used to infect 
K562 cells and transgene expression was evaluated by RT-PCR analyses as described 
above. These results are shown in Figure 18B. Whereas no transgene expression occurred 
after transduction with the scAAV2-HS234 vector or the scAAV2- βp-β87+-globin vector 
alone, as expected, significant expression was detected after co-infection when the two 
vectors were in a C-C orientation, which was 6-fold higher than when the two vectors 
were in an C-O orientation (Figure 18C). A similar study, using split enhanced green 
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fluorescent protein (EGFP) vectors, provided evidence that the C–C orientation is more 
efficient than the C-O or O-O orientation for intermolecular recombination between 
scAAV genomes (Choi et al., 2005). 
 
 
 
Figure 18: A) Schematic structures of scAAV2-βp-β87+-globin (i), scAAV2-HS234 (ii), 
and scAAV2-HS432 (iii) vectors. B) Comparative analysis of dual vectors-mediated β-
globin gene expression in K562 cells. Equivalent numbers of cells were either mock-
infected (Mock) or infected with single or dual vectors under identical conditions. The 
rest of the steps were the same as described in the legend to Figure 17. C) Densitometric 
scanning of autoradiographs in (A). 
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I. AAV2 and AAV1 serotypes are the most efficient in transducing K562 cells 
in vitro 
 In order to determine the most efficient serotype for the transduction of K562 
cells,  equal number of cells were infected with scAAV 1, 2, 7, 8 and 10 vectors under the 
control of  HS2-β-globin and B19p6 promoters and transgene expression evaluated by 
FACS 72 hrs post- infection. These results are shown in Figure 19. Whereas scAAV1-
B19p6-EGFP and scAAV2-B19p6-EGFP vectors mediated high efficiency transduction 
of K562 cells (40-67%), expression from scAAV10-B19p6-EGFP was moderate (10%), 
while expression from scAAV1-HS2-βp-EGFP and scAAV2-HS2-βp-EGFP was 5-6%.  
 
 
 
Figure 19: Comparative analysis of AAV serotype vector 1,2,7,8 & 10 containing B19p6 
or HS2-β-globin promoter-driven EGFP expression in K562 cells. Approximately, 
50,000 cells were mock-infected or infected with scAAV vectors at 37
o
C for 2 hr. 
Transgene expression was evaluated 72 hr post-infection by flow cytometry on a 
FACStar instrument. Data shown represents the average from two different experiments. 
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J. Efficient expression of β87+-globin gene occurs from human parvovirus B19 
promoter in the absence of β-globin gene enhancer elements 
 Although the dual-vector approach worked, the extent of transgene expression 
was not significantly enhanced compared with that from a single scAAV2-HS2-βp-β87+ -
globin vector. Because the human parvovirus B19 promoter at map unit 6 (B19p6) is a 
strong viral promoter, expression from which is restricted to differentiating hematopoietic 
erythroid progenitors (Ozawa et al., 1986; Ozawa et al., 1987)and because it is small (200 
bp),we sought to determine whether expression of the  β87+-globin gene could be 
obtained from the B19p6 promoter alone, and whether expression from the scAAV2- 
HS2-βp-β87+-globin vector Figure 20A, i) could be superseded by that from the 
scAAV2-B19p6-β87+-globin vector (Figure 20A, ii). In these studies we also included 
AAV serotype 1 (AAV1), on the basis of our preliminary studies with the EGFP reporter 
gene that showed that scAAV1 vectors mediate significant transduction of K562 cells 
(Figure 19). ScAAV2 and scAAV1 vectors containing either the HS2-βp-β87+-globin or 
B19p6-β87+ -globin genome were used to infect K562 cells and transgene expression 
analyses were performed as described above. These results are shown in Figure 20B.  It is 
evident that expression from the scAAV-B19p6-β87+-globin vector, even in the absence 
of the HS2 enhancer element, was 4-fold higher than expression from the scAAV-HS2-
βp-β87+-globin vector in both AAV2 and AAV1 serotypes (Figure 20C). The expression 
levels were further corroborated when using mutant primers (Pr. mutA and Pr. mutB; 
Figure 21A). The use of this primer pair leads to amplification of only the transduced 
β87+-globin transcripts, and yields a 290-bp product, which can be cleaved by Pvu II to 
generate 240- and 50-bp fragments. This primer set also amplifies a 384-bp DNA product 
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from the input vector genomes, which is cleaved by Pvu II to generate 334- and 50-bp 
fragments. The 384-bp DNA fragment generated in the absence of RT can also be 
cleaved with Pvu II, which indicates that the PCR product was derived from the 
recombinant AAV vector genome. As can be seen in Figure 21B, expression from the 
scAAV-B19p6-β87+-globin vector was 3- and 13-fold higher than expression from 
scAAV-HS2-βp-β87+-globin vectors in serotypes 2 and 1, respectively (Figure 21C). 
Although the vector copy number was higher in scAAV- HS2-βp-β87+-globin vector-
transduced cells, expression levels were still lower than in scAAV-B19p6-β87+-globin 
vector-transduced cells. Densitometric scanning and quantitation of the signals in Figure 
21B revealed the ratios of the vector genome copies and the β87+-globin transcripts to be 
0.15–0.5 for scAAV-HS2-βp-β87+-globin vectors, and 3.0 for scAAV-B19p6-β87+-
globin vectors. These results corroborate the ability of the B19p6 promoter to mediate 
high-efficiency β-globin gene expression in the complete absence of β-globin gene 
enhancer elements, and suggest that high-level expression of the β-globin gene from the 
B19p6 promoter might be achievable in primary human erythroid progenitor cells. 
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Figure 20: A) Schematic structures of scAAV-HS2-βp-β87+-globin (i), and scAAV-
B19p6-β87+-globin (ii) vectors. B) Comparative analysis β-globin gene expression in 
K562 cells. Equivalent numbers of cells were either mock-infected (Mock) or infected 
with each vector genome encapsidated in AAV2 or AAV1 serotype under identical 
conditions. The rest of the steps were the same as described in the legend to Figure 17. C) 
Densitometric scanning of autoradiographs in B). 
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Figure 21: A) Nucleotide sequence alignment of relevant codons of the endogenous β-
globin and the anti-sickling β87+-globin genes. The schematic structure of the β-globin 
cDNA, relative positions of the mutant primers (Pr. mutA and Pr. mutB), and the 
expected sizes of DNA products, with and without Pvu II digestions, from both the 
cDNA and the vector genome are indicated. (B) Comparative analysis of β-globin gene 
expression in K562 cells. Equivalent numbers of cells were either mock-infected (Mock) 
or infected with each vector genome encapsidated in AAV2 or AAV1 serotype under 
identical conditions. The rest of the steps were the same as described in the legend to 
Figure 17. (C) Densitometric scanning of autoradiographs in B). 
 
 
K. Efficient expression of β-globin protein occurs after transduction of human 
erythroid cells with AAV2-β-globin, and primary murine hematopoietic 
stem/progenitor cells with AAV1-β-globin, serotype vectors 
 Because all previous studies were limited to expression from the B19p6 promoter 
at the transcriptional level, we next evaluated whether the β-globin gene was also being 
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expressed at the protein level. To this end, we infected K562 cells and primary murine 
hematopoietic progenitor (c-kit
+
, lin
-
) cells with scAAV2-B19p6-β87+-globin and 
scAAV1-B19p6-β87+-globin vectors, respectively. Mock-infected and vector-infected 
cells were analyzed for β-globin protein expression 3 days post-transduction for K562 
cells, and 7 days post-transduction for primary murine c-kit
+
 lin
-
 cells. Briefly, mock- and 
vector-transduced cells were fixed, permeabilized, and stained intracellularly with PE-
conjugated mouse anti-human β-globin antibody, and β-globin protein was detected by 
flow cytometry. These results are shown in Figure 22. In K562 cells transduced with 
scAAV2-B19p6-β87+-globin vector, 30% of cells expressed vector-derived β-globin 
protein (Figure 22A). Approximately 13% of globin protein expression observed in 
mock-transduced K562 cells stained with Hb-PE antibody was due to the fact that the 
antibody also cross-reacted with the endogenous δ-globin protein, which is expressed in 
K562 cells. Thus, ~17% of scAAV2-B19p6-β87+-globin vector-transduced K562 cells 
expressed the β87+-globin protein (Figure 22B). Similarly, primary murine c-kit+, lin- 
cells were either mock-infected or infected with scAAV1-B19p6-β87+-globin vectors 
under identical conditions, and half of the cells were cultured in stem cell medium 
(complete IMDM containing IL-3 [10 ng/ml], IL-6 [10 ng/ml] and stem cell factor (SCF) 
[1 ng/ml]) supplemented with erythropoietin (scAAV+EPO), and the other half were 
cultured in stem cell medium lacking EPO (scAAV-EPO). β-globin protein expression 
was determined 7 days post-transduction essentially as described above. As can be seen 
in Figure 22C and D, ~16% of primary murine c-kit
+
, lin
-
 cells expressed vector-derived 
β87+-globin protein in the absence of EPO-treatment, and ~24% of these cells expressed 
vector-derived β87+-globin protein following EPO-treatment, which is known to induce 
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erythroid-differentiation. The β-globin protein-expressing cells were also CD71 
(transferrin receptor)-positive, which suggests, but does not prove, that the transgene 
expression was restricted largely to the erythroid lineage.  Approximately 5% of β-globin 
signal in mock-transduced cells stained with Hb-PE antibody was considered background 
since mouse anti-human β-globin antibody does not cross-react with the mouse 
endogenous β-globin protein.  
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Figure 22: A) Fluorescence-activated cell sorting (FACS) analyses of expression of the 
β-globin protein in human K562 cells. Cells were either mock-transduced (Mock) or 
transduced with scAAV2-B19p6-β87+-globin vectors and β-globin protein expression 
was determined 3 days post-transduction. Representative dot-plots are shown. Mock-
transduced K562 cells were stained with isotype control [Mock-Isotype; (i)], and Hb-PE 
antibody [Mock-Hb-PE; (ii)], and vector-transduced cells were stained with Hb-PE 
antibody [scAAV-Hb-PE; (iii)]. B) Quantitation of the data in A), corrected for the 
human δ-globin protein expression, represent the average expression levels from two 
experiments.  C) FACS analyses of expression of the β-globin protein in primary murine 
c-kit
+
, lin
-
 cells.  Equivalent numbers of cells were either mock-transduced (Mock) or 
transduced with scAAV1-B19p6-β87+-globin vectors under identical conditions. Half of 
the c-kit
+
, lin
-
 cells were cultured in stem cell medium supplemented with erythropoietin 
(scAAV+EPO), and the other half were cultured in stem cell medium lacking EPO 
(scAAV-EPO). β-globin protein expression was determined 7-days post-transduction 
essentially as described above. Mock-transduced c-kit
+
, lin
-
 cells were stained with 
isotype control [Mock-Isotype; (i)], and Hb-PE antibody [Mock-Hb-PE; (ii)], and vector-
transduced cells grown either in the absence [scAAV-EPO; (iii)] or presence of EPO 
[scAAV+EPO; (iv)] were stained with Hb-PE antibody. D) Quantitation of the data from 
C) represents the average expression levels from two experiments. 
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L. Self-complementary AAV-β87+-globin vectors fail to mediate efficient 
transduction of hematopoietic stem cells from sickle cell disease mouse model 
in vivo 
 We next wished to determine whether scAAV-B87
+
-globin vectors could also 
mediate efficient transduction and globin gene expression in a sickle cell disease (SCD) 
mouse model. Sca1
+
, c-kit
+
, lin
-
 cells from BERK mice were transduced as described in 
Material and Methods. A total of fifty mice were transplanted with the SCD cells, but 
only 5 survived for more than 2 weeks indicating that the SCD HSCs failed to rescue the 
irradiated animals, which would have allowed survival. Unfortunately, however, none of 
the mice that survived showed any globin expression following HPLC, globin chain and 
IEF analysis, as shown in Figure 23 A, B and C respectively.  All mice expressed the 
endogenous mouse globin likely due to inefficient total body irradiation and recovery by 
a few mouse stem cells.  Two of the mice (BERK-AAV1-βp-globin and BERK-AAV7-
p6-globin) also expressed sickled globin, indicating that while engraftment did occur, 
these cells failed to be transduced by the scAAV-globin vectors.   
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Figure 23A: Analysis of human β-globin expression in SCD mice. Peripheral blood was 
drawn from the retroorbital sinus of mock and vector treated donor recipient mice 3 
months post-transplant and analysed using HPLC.  
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Figure 23B: Analysis of human β-globin expression in SCD mice. Peripheral blood was 
drawn from the retroorbital sinus of mock and vector treated donor recipient mice 3 
months post-transplant and analysed using globin chain analysis.  
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Figure 23C: Analysis of human β-globin expression in SCD mice. Peripheral blood was 
drawn from the retroorbital sinus of mock and vector treated donor recipient mice 3 
months post-transplant and analysed using isoelectric focusing analysis.  
 
 
 
 
 
 84 
This conclusion was further corroborated by qPCR analyses in which HSCs from 
SCD mice were documented to be non-permissive for entry of recombinant AAV1 and 
AAV7 serotype vectors.   These results are shown in Table 4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: AAV1 and AAV7 fail to enter HSCs from SCD mice. HSCs from SCD mice 
were mock or vector transduced using AAV1 through AAV10 serotype vectors for 2hrs 
as described in Material and Methods. Vector copy number per cell was analyzed by 
qPCR. 
 
 
 
 
 
 
 
 
 
 
AAV vector 
Copy 
No./cell 
Mock 0.2 
AAV1 24 
AAV2 198 
AAV3 108 
AAV4 17 
AAV5 762 
AAV6 67 
AAV7 264 
AAV8 4928 
AAV9 1506 
AAV10 39 
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DISCUSSION  
  Controversies exist regarding the ability of adeno-associated virus 2 to transduce 
human hematopoietic stem cells. While some groups believe that AAV2, does not 
transduce human HSCs (Alexander et al., 1997), and that the observed transduction was a 
result of viral contaminants, others believe that AAV2 vectors transduce human HSCs at 
high vector to cell ratio (Hargrove et al., 1997; Malik et al., 1997; Nathwani et al., 2000). 
Still, we and others have shown efficient and sustained transduction of human and murine 
HSCs by AAV2 vectors at a low vector to cell ratio (Fisher-Adams et al., 1996) 
(Chatterjee et al., 1999; Li et al., 2005; Ponnazhagan et al., 1997a; Ponnazhagan et al., 
1997b; Santat et al., 2005; Tan et al., 2001b; Zhong et al., 2004b; Zhong et al., 2004a; 
Zhong et al., 2006a; Maina et al., 2008a and b). These controversies are beginning to be 
resolved through a thorough assessment of the factors that limit transduction of murine 
and human HSCs and these observations have previously been reviewed. (Srivastava., 
2002; Srivastava., 2005; Zhong et al., 2006a). Briefly, transduction of HSCs is limited by 
i) Suboptimal levels of the receptor/co-receptor for AAV2 which limits viral binding and 
entry, ii) Impaired intracellular trafficking and viral uncoating, iii) Inefficient conversion 
of AAV genome to transcriptionally active genomes through viral second strand 
synthesis, iv) Low CMV-promoter mediated transgene expression (Zhong et al., 2004b; 
Zhong et al., 2006a).  
 Since only a small percentage of murine HSCs express the receptor and co-
receptor for AAV2, and conventional, single-stranded AAV2 vectors do not infect this 
population, we generated modified, self-complementary AAV vectors encapsidated in 
alternative AAV serotypes 1, 7, 8 and 10. The rationale was that murine HSCs may 
express the receptor/co-receptor for at least some of these novel AAV serotypes and 
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would allow efficient binding and entry. In consistence with our previously published 
results, AAV1 serotype vector was the most efficient in transducing primary murine 
HSCs in liquid cultures in vitro and in vivo (Li et al., 2005). In addition, expression from 
AAV7 serotype was also efficient, at 16% and 32% with the HS2-β-globin- and 
parvovirus B19p6- promoters, respectively. We also observed transduction by scAAV2 
vector indicating that conversion to transcriptionally active genomes and suboptimal 
promoters were the main limiting factors in transduction by ssAAV2 vectors. This 
assessment is based on the assumption that self-complementary AAV vectors do traffic 
and uncoat in a manner similar to that of conventional, single stranded vectors. 
Expression from scAAV8 and scAAV10 was efficient and similar to that of scAAV2, 
indicating that murine HSCs express the receptors for serotype 8 and 10. AAV8 serotype 
has been shown to undergo more rapid uncoating in murine hepatocytes compared to 
AAV2 (Thomas et al., 2004) and it remains to be tested whether this occurs in murine 
HSCs.  
 Since the CMV promoter is weak and sensitive to silencing in hematopoietic cells 
(Choi et al., 2001; Kung et al., 2000; O'Rourke et al., 2005), we employed the use of  
erythroid-specific eukaryotic β-globin- and parvovirus B19p6- promoters. In this study, 
we were able to demonstrate erythroid lineage restricted expression using the eukaryotic 
HS2-β-globin and parvovirus B19p6 promoters.  Higher level erythroid restricted, 
transgene expression was detected from the parvovirus B19p6 promoter when compared 
to HS2-β-globin promoter despite the absence of HS2 in these vectors. No significant 
expression was detected in any other lineage in both primary and secondary transplant 
experiments in all serotypes tested. Although HSCs give rise to cells in several lineages, 
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expression of the HS2-β-globin- and parvovirus B19p6- promoters was restricted to the 
erythroid lineage. EGFP expression was readily detected in the erythroid lineage 9 
months after primary transplantation, indicating that a stem cell with long term 
repopulation ability had been transduced. While previous reports have shown efficient 
transgene expression from the B19p6 promoter in human erythroid progenitors (Kurpad 
et al., 1999; Wang et al., 1995b), this is the first study to show efficient, erythroid 
restricted expression in murine erythroid progenitors.  
 Extensive integration analysis of AAV2 vectors has been performed in various 
murine tissues and it is believed that AAV2 does not integrate in murine cells.  It is 
generally assumed that recombinant AAV vector genomes remain episomal, but those 
studies have been carried out in tissues that are post-mitotic, where there is no pressure 
for AAV to integrate (Duan et al., 1998; Inagaki et al., 2007; Nakai et al., 2003; Nakai et 
al., 2005).  However, in an actively dividing tissue like the bone marrow, it is likely that 
AAV integrates to avoid loss of vector genomes. Using southern blot analysis, we were 
able to show evidence of vector genomes in mouse bone marrow cells 9 months post 
primary transplant, suggesting that AAV integrates in dividing cells.  However, further 
studies are needed to determine the site(s) of integration as well as the exact AAV 
chromosomal junctions. Some of this work, involving a larger cohort of mice has been 
performed in our laboratory and initial assessment suggests that AAV integrates 
randomly in the murine bone marrow (Han et al., 2008). 
 It is only recently that AAV has been reported to lead to insertional mutagenesis 
in the murine liver, resulting in hepatocellular carcinoma (Donsante et al., 2007).  
However, in these studies, AAV was injected in neonatal mice using very high viral 
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titers. Several other studies have not found any toxicity associated with AAV vectors 
even in p53-deficient mice (Bell et al., 2005; Bell et al., 2006; Schuettrumpf, 2007).  To 
determine whether AAV vectors were associated with any toxicity in the bone marrow, 
we performed morphological analysis of peripheral blood and bone marrow cells since 
only bone marrow cells had been infected. As reported in the results, no explicit 
deleterious effects were seen in the tissues tested; indicating that integration of AAV did 
not result in any obvious toxicity. Since not all mutations are associated with overt 
pathologic findings, extensive integration studies are warranted. 
 Autologous bone marrow transplantation with genetically modified cells would be 
a great treatment modality for sickle cells disease (SCD), but has been limited by the 
inability to achieve therapeutic levels of β-globin expression in the HSC’s progeny 
(Sadelain, 1997; Sadelain, 2006). Recently, lentiviral vectors have been used to obtain 
high-level expression of globin gene cassettes leading to therapeutic correction of several 
murine models of sickle cell disease (Levasseur et al., 2003; Pawliuk et al., 2001). 
Recombinant AAV2 vectors are a safer alternative to retroviral and lentiviral vectors for 
successful gene therapy of human disorders. In this study, we sought to improve 
recombinant AAV2 mediated β-globin gene expression, by employing the use of scAAV 
vectors expressing anti-sickling β-globin gene under the control of erythroid cell-specific 
promoters (HS2-β-globin and parvovirus B19p6 promoters). 
 In the first set of studies involving comparative analysis of conventional single 
stranded AAV2 vectors to double stranded, self complementary AAV2 vectors, it is 
apparent that double stranded AAV2 vectors were more efficient in transducing K562 
cells in vitro.  Although the scAAV2 vector contained only one enhancer element, it was 
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able to bypass the second strand synthesis step, leading to efficient transduction of K562 
cells.  
 Since the transduction efficiency of scAAV2 vectors was better than that of 
ssAAV2 vectors, we hypothesized that a vector containing β-globin under the control of 
the entire locus control cassette (HS2+HS3+HS4) in a double stranded genome would 
have better transgene expression. Given that the size limitation of scAAV2 vectors is 3.3 
kb (Wu et al., 2007), we employed the dual-vector approach. In this strategy, a single 
gene is split into two separate scAAV vectors, which then undergo intermolecular 
recombination following cellular entry and viral uncoating. Following co-infection of 
either scAAV2-HS234/scAAV2-HS432 vector with the ds-βp-globin vector, transgene 
expression was observed from both groups.  However, expression from the scAAV2-
HS234 (C-C) vector was 5.6-fold greater than that from the scAAV2-HS432 vector (C-
O). Using a split GFP vector, Choi et al. (Choi et al., 2005) demonstrated that the closed-
to-closed ITRs were more efficient than the closed-to-open or the open-to-open ITRs at 
undergoing recombination. These results indicate that the dual vector approach can be 
applied to globin gene transfer although the transduction efficiency is still low. Ghosh et 
al has shown that the efficiency of dual vector recombination can be improved by 
including a portion of the alkaline phosphatase gene in the scAAV vectors (Ghosh et al., 
2008). 
 Our studies also demonstrate that the parvovirus B19p6 promoter can be used to 
mediate efficient expression of the β-globin gene at the protein level, even in the absence 
of the β-globin gene enhancer elements in human as well as primary murine 
hematopoietic stem/progenitor cells. To our knowledge, expression of the β-globin gene 
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has never been achieved without the use of the β-globin enhancer elements. The 
implications of this observation are two-fold.  First, the small size of the B19p6 promoter 
not only allows the generation of scAAV-β-globin vectors, but also overcomes the 
stringent regulations of transcriptional control of the β-globin gene. And second, since 
expression from the B19p6 promoter leads to production of potentially therapeutic levels 
of the β-globin protein in primary murine hematopoietic progenitor cells, this bodes well 
for its potential utility presumably in primary human erythroid progenitor cells.  
 Although we demonstrated efficient transduction and erythroid lineage-restricted 
expression using AAV serotype vectors 1 and 7 in HSCs in C57BL/6 mice, we were not 
successful in demonstrating efficient transduction or transgene expression of anti-sickling 
globin gene is a SCD mouse model. The failure to demonstrate this was likely due to:  i) 
failure of AAV vectors to transduce SCD mouse HSC or, ii) failure of SCD HSCs to 
engraft in C57BL/6 strain. SCD mice were generated using FVB/N mouse eggs and 
consist of a mixture of FVB/N, 129, DBA/2, Black Swiss and C57BL/6.  One attempt to 
correct this entails backcrossing of the SCD mice into C57BL/6, which would generate a 
mouse model more similar to C57BL/6. With this strain, we would likely be able to 
demonstrate not only efficient transduction but also expression of therapeutic levels of β-
globin and phenotypic correction of the SCD phenotype. Another likely explanation for 
the failure of these experiments was the failure of engraftment of SCD HSCs in 
C57BL/6.  Although fifty animals were transplanted with the SCD cells, only a small 
number of animals survived for more than 2 weeks indicating that the SCD HSCs failed 
to rescue the irradiated animals, which would have allowed survival. All animals that 
survived had mouse globin chains in addition to the sickling globin. One likely 
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explanation is that the SCD HSCs are less viable that those from C57BL/6 or the SCD 
HSC induced a graft versus host reaction in the C57BL/6 recipients resulting in grafting 
failure.   
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FUTURE RESEARCH DIRECTIONS 
 In this work, I have demonstrated efficient transduction and erythroid lineage-
restricted expression using AAV serotype vectors in HSCs from C57BL/6, but not those 
from SCD mice.  Thus, AAV vector-mediated transduction of HSCs from other mice 
strains still needs to be thoroughly studied.  One attempt to correct this would entail 
backcrossing of the SCD mice into C57BL/6 that would generate a mouse model more 
similar to C57BL/6. With this strain, it should be possible to demonstrate not only 
efficient transduction but also expression of therapeutic levels of β-globin and phenotypic 
correction of the SCD phenotype mediated by scAAV1 and scAAV7 serotype vectors. 
 An additional approach to improve transduction and erythroid lineage-restricted 
expression of globin gene in mouse and human HSCs would be to extend these studies to 
include additional novel AAV serotypes vectors such as AAV6, AAV9, AAV11, and 
AAV12. It is likely that such studies would help identify a novel serotype(s) with which 
better transduction of murine and/or human HSCs would become feasible. It is also likely 
that one or more of these novel AAV serotypes would exhibit tropism for SCD HSCs, 
and would thus mediate not only efficient transduction of these cells but also allow 
phenotypic correction of the SCD in this mouse model.  
 Li and colleagues demonstrated that AAV7 followed by AAV8 and AAV1, were 
the most efficient in transducing human CD34
+ 
cells (Li et al., 2005). However, these 
studies were performed using conventional single-stranded vectors under the control of a 
non-erythroid promoter.  Thus further studies should be carried out to compare the 
transduction efficiencies of AAV serotype 1, 7, 8 and 10 vectors containing the B19p6 
promoter in these cells in vitro and in NOD/SCID mice in vivo. However, since human 
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CD34
+
 cells do not efficiently reconstitute the erythroid lineage in NOD/SCID mice, 
CFU assays could be performed using cells from spleen, PB and BM from these mice. 
Globin gene expression analysis could also be performed on CFU-erythroid-enriched 
population to increase the chances of detecting vector-derived globin gene expression. 
Since endogenous AAV sequences are the third most prevalent in the human marrow, an 
alternative strategy would be to isolate a novel AAV serotype(s) from pooled human 
CD34
+
 cells. It is likely that one of these serotypes possesses tropism for CD34
+
 cells, 
which, in turn, should allow the development of a novel AAV serotype vector(s) capable 
of high-efficiency transduction of human CD34
+
 cells.  
 With the recent development of novel tyrosine mutant AAV vectors that allow 
high-efficiency transduction and expression of therapeutic levels of human factor IX 
protein in murine hepatocytes from BALB/c, C3H/HeJ and C57BL/6 in vivo (Zhong et 
al., 2008), because these vectors bypass ubiquitination and proteasome-mediated 
degradation, it is likely that one of these mutant vectors would mediate efficient 
transduction of HSCs from SCD mice and/or human CD34
+
 cells given their ability to 
mediate transduction in several mouse strains. Although initial preliminary studies have 
demonstrated efficient transduction of human CD34
+
 cells by several of these tyrosine 
mutant vectors in vitro and in vivo, further studies should be pursued to identify the 
optimal tyrosine mutant vector(s) for efficient transduction of murine and human HSCs 
for globin gene transfer. In addition, tyrosine mutants of AAV serotypes 1, 7, 8, 9 and 10 
vectors could also be generated and tested to examine whether improvement in 
transduction of these cells at low vector to cell ratio would be achieved in vitro and in 
vivo.  
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 The ultimate objective is to perform clinical trials using SCD HSCs from patients. 
However, prior to that, safety and efficacy of stable transduction and erythroid lineage-
restricted expression of a transgene must be rigorously established in a non-human 
primate model. Although successful transduction of CD34
+
 cells from Rhesus monkeys 
by conventional single-stranded AAV2 vectors has been demonstrated in the past 
(Schimmenti et al., 1998), studies should be contemplated to determine these parameters 
in cynomolgus monkeys since these monkeys can be infected by parvovirus B19, and 
abundant expression from the B19p6 promoter occurs in erythroid progenitor cells from 
these monkeys (Gallinella et al., 1995). Thus, it can be anticipated that recombinant 
scAAV-B19 hybrid vectors or novel tyrosine mutant AAV serotype vectors will mediate 
high-efficiency transduction and erythroid lineage-restricted expression in these animals. 
Additional studies on stable transduction of HSCs, long-term expression of therapeutic 
levels of globin gene in erythroid cells by AAV vectors, and determination of possible 
deleterious effects, if any, should also be performed. And finally, attempts should be 
made to isolate novel AAV serotypes from CD34
+
 cells from cynomolgus monkeys as 
well as from humans since several novel AAV serotypes have indeed been isolated from 
various tissues from non-human primates and humans (Chen et al., 2005; Gao et al., 
2004), and the successful development of these novel AAV serotypes into recombinant 
vectors should prove useful in the potential gene therapy of hemoglobinopathies in 
general, and β-thalassemia and sickle cell disease in particular. 
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